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Chapter 1 
Mycetoma and Madurella mycetomatis infection 
Abdalla 0. A. Ahmed 
Chapter 1 
THE DISEASE MYCETOMA 
Mycetoma is a chronic granulomatous infection caused by either true fungi or actinomycetes. Fungal 
mycetoma is known as "eumycetoma" while bacterial mycetoma is known as "actinomycetoma". A 
subcutaneous mass and multiples sinuses draining pus, blood and grains characterize the mycetoma 
lesion. Grains or "sclerotia" are aggregates of the fungal hyphae or the bacterial filaments sometimes 
embedded in hard cement-like material. The morphological characteristics of the grains may give a 
clue about the species nature of the possible causative agents (9). It is suggested that the infection 
starts subcutaneously after traumatic inoculation of the microorganisms, which are thought to live as 
saprophytes in soil and perhaps other natural ecological niches. The mycetoma infection has a 
prolonged and indolent course. The infection progresses slowly over a long period of time without 
painful manifestation. The mycetoma lesion may ultimately extend to the deep tissues and bones, 
leading to deformity of the affected site and subsequent disability. Mycetoma infection is not self-
curing and, if untreated, always leads to massive lesions, which at the end necessitate surgical 
amputation. The disease is severely debilitating, especially the lesions that arise in the extremities 
(25). The socio-economic consequences of the disease are severe. 
The first case of mycetoma was reported by Dr. John Gill as "Madura foot" in a dispensary report of 
the Madras Medical Service of the British Army in India 1842 (61 ). The existence of the disease was 
confirmed by Colebrook more than a century later in 1946. The term "mycetoma" was first used by 
Vandyke Carter in 1860 (61). However, it is certain that mycetoma has a prolonged history. 
Heshkovitz et a!. in 1992 presented a skeleton of a woman who lived during the Byzantine period 
(300- 600 AD) with pathological changes in the low extremities. This case was proposed to be the 
oldest known case of mycetoma, but was later re-diagnosed as a case of leprosy after the molecular 
analysis of the bones (37, 65). 
EPIDEMIOLOGY AND ETIOLOGY OF MYCETOMA 
Mycetoma has a worldwide distribution, which is, however, extremely uneven. Mycetoma is endemic 
in tropical and subtropical regions and the African continent seems to be the area of the highest 
prevalence (Figure 1 ). Worldwide, mycetoma prevails in the mycetoma belt that stretches between the 
latitudes of 15° South and 30° North (9, 44). The belt includes Sudan, Somalia, Senegal, India, 
Yemen, Mexico, Venezuela, Columbia, Argentina and other countries (44, 46, 50). In Africa, 
mycetoma is most frequently seen in Sudan, Senegal, Mauritania, Kenya, Niger, Nigeria, Ethiopia, 
Chad, Cameroon, Djibouti and Somalia (1, 2, 5, 11, 17, 18, 43, 64). In Sudan, Abbot noted the 
admission of 1231 mycetoma cases to out-patient clinics throughout the country within a period of two 
and a half years (1 ). Lynch in 1964 gave an estimation of 300 - 400 new cases per year in Sudan (43). 
It has been extensively reported in India (8, 64). In addition, mycetoma has been reported in many 
temperate regions as well. Most of those cases were immigrants who probably contracted the infection 
in their home countries. This usually complicates the clinical diagnosis of this mycosis since it is 
frequently unexpected (15). There were reports on mycetoma from the United States, Ceylon, 
Germany, Egypt, Turkey, Philippines, Japan, Lebanon, Thailand, Iran, The Netherlands and Saudi 
Arabia (12, 15, 22, 24, 30, 40, 67). 
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Areas where mycetoma prevails are relatively arid with a short rainy season of 4-6 months. Rainfall is 
50 to 1000 mm per year, with a relative humidity of 60-80% and fairly constant temperatures of 30-
3rC for 24 hours a day. This is followed by a dry season of 6-8 months with a relative humidity of 12-
18%, day temperatures rising to 45-60°C. Temperatures may fall to 15-18°C during the night (49). This 
alteration in extreme weather conditions may be a prerequisite to the survival of the causative 
organism in its natural niche. 
Geographical distribution of the mycetoma causative agents shows considerable variations, which 
could be explained on these and other environmental factors, especially the rainfall (9, 49, 50). Many 
microorganisms are capable of causing mycetoma (Table 1 ). The most prevalent etiological agent of 
eumycetoma worldwide is Madurel/a mycetomatis (52). Most of the mycetoma cases in Africa are 
eumycetoma caused by M. mycetomatis. In some parts of central Africa, including Sudan, M. 
mycetomatis causes more than 70% of all mycetoma infections (9, 32). 
<t'> Pyrenochaeta romeroi 
+ Pyrenochaeta mackinnonii 
<> Leptosphaeria senegalensis 
+ Madurel/a grisea 
+ Madurel/a mycetomatis 
+ Madurel/a species 
Figure 1: Map showing the geographical distribution of some eumycetoma agents. 
SUSCEPTIBLE POPULATION AND RISK FACTORS 
All people living in the endemic area can be infected, but the infection is more common in herdsmen, 
farmers and other field laborers who have direct and frequent contact with the open environment. 
Males are five times more often affected by mycetoma than females, even in areas where both sexes 
engage in out-door activities (9, 28, 52). Mycetoma is seen in all age groups, but it usually affects 
adults between 20 and 40 years old (9, 28). Mycetoma is not considered to be transmissible from 
person to person or from animal to person. 
There are some conflicting reports about the role of the immune status of the susceptible population. 
Some investigators reported partial impairment of the cell-mediated immune response in patients 
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severely infected or not responding to medical treatment (48). In animals, some evidence supporting 
this hypothesis was reported, e.g. the more successful induction of mycetoma in athymic mice as 
opposed to immunocompetent mice (45). The more rapid progression of induced mycetoma in 
immunosuppressed goats in comparison to normal goats provided another pivotal evidence (33). In 
contrast, Bend! et al. did not observe a similar phenomenon (7). The humoral immune response has 
been evaluated by Wethered and his colleagues using an ELISA system (71 ). High lgM levels have 
been demonstrated in the majority of the patients with mycetoma due to M. mycetomatis, whereas low 
levels of lgA were detected in some of the patients (71 ). Sera from patients reacted better in ELISA in 
comparison to Western blots, indicating possible involvement of immunogenic polysaccharide 
antigens in M. mycetomatis infection (71 ). Immunoglobulin M and G and complement have been 
demonstrated on the surface of the grains and on the filaments inside the grains in case of 
actinomycetoma (21 ). 
CLINICAL PRESENTATION 
Mycetoma initially presents as a slowly progressive and painless subcutaneous swelling, sometimes in 
combination with a history of preceding trauma (9, 52). However, the incubation time before classical 
signs develop is not well-defined. The first symptoms may require several months to years to develop. 
Investigations are complicated by the fact that most of the patients tend to present late, due to lack of 
clinical symptoms, lack of accessible health care facilities, or due to fear of amputation (9, 52, 61 ). 
The duration of the disease, the type of causative organism, the site of the infection and possibly the 
immune response of the host, all affect the clinical presentation of mycetoma (28). However, patients 
with a short disease history may present with massive lesions and severe destruction of the deep 
tissue and even bones. In contrast, others may present with minor localized lesions existing already 
for a long time without any evidence of major progressive tissue destruction (Fahal, personal 
communication). The subcutaneous swelling is usually firm and rounded but it may as well be soft, 
lobulated. It is rarely cystic, but often mobile. The subcutaneous nodule increases in size and 
secondary nodules may evolve as well (28). The nodules may suppurate and drain through multiple 
sinus tracts and these sinuses may close transiently after discharge during the active phase of the 
disease. Fresh adjacent sinuses may open while some of the old ones may heal completely. The 
nodules are connected with each other, through deep sterile abscesses and with the skin surface (9, 
28). 
Mycetoma can affect any body site, not only the feet and the lower limbs (figure 2). Most of the cases 
are usually seen in the feet (70%), followed by hands (12%), then legs and knee joints. In highly 
endemic areas other parts of the body may be involved as well. These include the arm, head and 
neck, thighs and the perineum. Rare sites such as the chest and abdominal walls, facial bones, 
mandible, paranasal sinuses, eyelid, vulva, orbit, scrotum and old surgical incisions may be affected 
(9, 28). Mycetoma spreads locally or through the lymphatic system and rarely haematogenously. 
Secondary nodules may arise in the affected area, sometimes in combination with lymphatic spread in 
some advanced cases. Secondary sites are seen more often in actinomycetoma than in eumycetoma 
(9). Mycetoma is usually painless in nature, and it has been suggested that the mycetoma lesion 
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produces substances that have an anesthetic effect (25). At a late stage of the disease the absence of 
pain may be due to nerve damage by the tense fibrous tissue reaction, endarteritis obliterans or poor 
vascularisation of the nerves alternatively. Pain at the end may be produced by invasion of the bone or 
it may be due to secondary bacterial infection (3, 28). As the mycetoma granuloma increases in size, 
the skin may become smooth, shiny and areas of hypo- or hyper-pigmentation may develop. 
Increased local hyperhydrosis was also seen in some of the patients (9, 25). 
Table 1: Etiologic agents of eumycetoma and actinomycetoma grouped by appearance of typical 
intralesional grains. 
Eumycotic mycetoma 
Acremonium falciforme 
Acremonium ki/iense 
Acremonium recifei 
Cylindrocarpon cyanescens 
Cy/indrocarpon destructans 
Pseuda/lescheria boydii 
Fusarium oxysoprum 
Fusarium so/ani 
Fusarium moniliforme 
Hormonema spp. 
Aspergillus flavus 
Aspergillus nidu/ans 
Polycytella hominis 
Plenodomus avramii 
Corynespora cassiicola 
Curvularia geniculata 
Curvularia lunata 
Leptosphaeria senegalensis 
Leptosphaeria thompkinsii 
Madurella grisea 
Pseudochaetosphaeronema 
/arense 
Color of 
grains 
White 
White 
White 
White 
White 
White 
White 
White 
White 
Green 
White 
White 
Black 
Black 
Black 
Black 
Black 
Black 
Black 
Black 
Pyrenochaeta mackinnonii Black 
Pyrenochaeta romeroi Black 
Madurella mycetomatis Black 
Neotestudina rosatii White 
Exophiala jeanselmei Black 
Phialophora verrucosa Black 
* Based on references 32, 52, 58 and 61. 
DIAGNOSIS OF MYCETOMA 
Actinomycotic mycetoma 
Streptomyces somaliensis 
Actinomadura madurae 
Actinomadura peflitieri 
Actinomyces israe/ii 
Nocardia asteroides 
Nocardia brasiliensis 
Nocardia caviae 
Nocardia farcinica 
Nocardia transvalensis 
Nocardia dassonviflei 
Color of grains 
Yellow to brown 
White to yellow or pink 
Red 
White to yellow 
White 
White 
White to yellow 
White to yellow 
White 
Cream 
The clinical triad of a subcutaneous mass, sinuses, and discharge containing grains observed in 
patients from an endemic area is diagnostic for mycetoma. Since a variety of other agents may cause 
mycetoma, it is important to identify the causative agent in order to develop a correct plan of treatment 
(reference 9 and table 2). However, the available strategies are few and with many limitations. Direct 
examination of grains may be useful in determining the type of mycetoma. Unlike fungal grains, 
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crushed bacterial grains show fine filaments, which can be stained according to Gram. Isolation of 
mycetoma agents can be difficult, especially in case of the actinomycetes. Culture requires deep 
surgical biopsies containing grains. Biopsies without grains are not suitable for diagnosis (20). The 
large numbers of causative organisms, the poor in vitro differentiation of fungi that cause mycetoma, 
complicate the identification process (15). Histopathology is useful for confirming the clinical diagnosis 
of mycetoma and in differentiation of most of bacterial causes of mycetoma (table 1 ). Histopathological 
examination is generally unable to differentiate fungi. 
Few studies have focused on serology for early detection and monitoring patients under treatment (49, 
55, 66). However, these tests are relatively crude and problems of cross reactivity between 
actinomycetes exist. Low sensitivity, and lack of standardized antigen preparations are the other 
remaining problems (personal observation). Fine needle aspiration cytology for mycetoma has also 
been described and is considered to be a useful technology (19). Radiology helps in the clinical 
diagnosis, especially in the follow-up of disease progression, development of a surgical strategy and 
for assessing the clinical cure (9, 28, 52). 
MANAGEMENT OF MYCETOMA 
Proper management of mycetoma strongly depends on the identification of the causative organism. 
Eumycetoma should be treated with adequate antifungal therapy and surgery. Actinomycetoma 
responds to antibacterial treatment and in a few cases surgery is indicated (9). Early cases are 
curable, but advanced cases are difficult to treat. Advanced mycetoma always requires long term 
antimicrobial treatment in combination with aggressive surgery (9, 27). The aim of surgery is complete 
excision of small, well-encapsulated lesions, or the reduction of the amount of infected tissue to be 
cured by chemotherapy. Surgery has some undesirable effects. In order to perform effective surgery 
one needs to undertake aggressive excision or debridement under general anaesthesia, which usually 
cripples the limb or otherwise leads to permanent disability. Performing surgery without a combination 
of effective medical treatment has a high rate of recurrence (up to 90%). Early cases with well-
encapsulated lesions without bone involvement can be treated efficiently with surgery. In such cases, 
combination of medical treatment before and after surgery results in the most successful outcome (9, 
27,52). 
Figure 2: A: An early eumycetoma case; B: Eumycetoma lesion involving a lymph node containing 
numerous black grains; C: Massive mycetoma in the buttock; D: The second common site for 
mycetoma, the hand; E: Inguinal lymph node involvement after lymphatic spread; F and G: massive 
eumycetoma and actinomycetoma of the foot, respectively. 
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Table 2: The main clinical differences between eumycotic and actinomycotic mycetoma. 
Eumycetoma Actinomycetoma 
Causative agents Fungi Bacteria 
Lesion characteristics Well-encapsulated with a clear margin Diffuse, no clear margin 
Sinuses Relatively few Many 
Color of grains Different colors, but mostly white or black Different colors, other than black 
Course of infection Slowly progressive More inflammatory and rapid progression 
Bone invasion After a long time Rapid 
Small in number, but large in size with 
Numerous, small in size (except in case of 
Cavities in X-ray Actinomadura madurae) with unclear 
clear margins 
margins 
Management 
! Dapsone + streptomycin 
! Ketoconazole 
Drug of choice ! Rifampicin or fansidar 
! ltraconazole 
! Amikacin + cotrimoxazole 
! Only medical treatment is 
! Both medical and surgical sufficient (in some advanced 
Management of choice 
intervention required cases in combination with 
surgery) 
! May cure small, well-
Surgery only 
encapsulated lesions 
Not indicated ! 
! Up to 90% recurrence in 
most cases 
! Partial cure or improvement 
! Recommended before 
Medical treatment only 
surgery to prevent local 
Useful in most of cases ! 
spread 
! Needed after surgery to 
prevent recurrence 
! Early diagnosis followed by 
! Early diagnosis followed by 
Most successful outcome 
adequate antifungal 
medical treatment for a 
treatment in combination 
with surgery 
sufficiently long period 
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THE GENUS MADURELLA AND ITS TWO SPECIES 
The majority of the Sudanese eumycetoma are caused by the fungus M. mycetomatis. Madurella 
species in general are slow-growing fungi that produce dark colonies composed of a dense, 
melanized, and mostly sterile mycelium. Madurella species are well known agents of black-grain 
mycetoma. Two species are recognized, M. mycetomatis and M. grisea (16). Brumpt in 1905 replaced 
an organism described by Laveran 1902 as Streptothrix mycetomi, to the genus Madurella. The 
fungus was known as Madurella mycetomi for more than seven decades. In 1977, the British 
Research Council published Memorandum No. 23 ("Nomenclature of Fungi Pathogenic to Humans 
and Animals") in which the name was corrected to M. mycetomatis. The name was corrected because 
the specific epithet must be in the genitive case (the Madurella of mycetoma). As the mycetoma is a 
Greek neuter noun, the correct citation is mycetomatis (41, 61 ). 
In different culture media, M. mycetomatis shows various colonial morphologies (figure 3). The growth 
rate is moderate, and the colonies are white and wooly at first, becoming olivaceous, yellow, or brown, 
generally producing a brownish diffusible pigment. In poor media, sclerotia being 750 11m in diameter 
may develop (58). Colonies are mostly sterile, composed of dense melanized mycelium. No efficient 
sporulation has ever been observed. However, phialides with minute conidia in short chains and 
cellarettes may be observed (16, 52, 58). Some investigators reported that better sporulation was 
observed when M. mycetomatis was cultured 
Figure 3: Cultures of M. mycetomatis clinical isolates on Sabouraud dextrose agar after 3 weeks 
incubation at 37° C. 
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in straw extract agar, wheat extract agar, soil extract agar, or water agar (41, 59). In most cases, the 
microscopic appearance of M. mycetomatis and M. grisea is quite similar. Both fungi show the sterile, 
dense by melanized mycelia. Some isolates of M. grisea were reported to form pycnidia. Such isolates 
are indistinguishable from Pyrenochaeta mackinnonii (58). Species-differentiation of M. mycetomatis 
and M. grisea can be made by differences in sugar assimilation and optimal growth temperature. M. 
mycetomatis assimilates lactose but not sucrose, while M. grisea assimilates the other way around. M. 
mycetomatis grows well at 37°C, while M. grisea does not grow at 37°C (growth obtained at 30°C) 
(16, 58). This may also explain the observed difference in virulence. 
Figure 4: Histological sections of M. mycetomatis eumycetoma in a mammalian host. Slides A and C 
were stained with PAS staining (200x), slide C with Grocott methenamine silver stain (400x) and slide 
D with Hematoxylin and Eosin (350x). 
PATHOLOGY OF M. MYCETOMA TIS INFECTION AND ULTRASTRUCTURE OF THE LESION 
In tissues, M. mycetomatis forms numerous black sclerotia (grains). Grains are vegetative aggregates 
of the fungal mycelia embedded in a hard brown matrix (reference 20 and figure 4). This matrix 
consists of extracellular cement that appears to be 1, 8-dihydroxynaphthalene melanin in combination 
with host tissue debris and a specific protein. This rigid matrix may act as a barrier protecting the 
fungus from the natural immunity of the host and antifungal agents (52). Melanin-like pigments in the 
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dimorphic fungal pathogen Paracoccidioides brasiliensis are detected in vitro and in vivo, suggesting 
a possible role in the pathogenesis of Paracoccidioidomycosis (31 ). The grains have different shapes 
and sizes. In stained sections, the grain is mostly rounded, oval or trilobed. Two types of grains are 
recognized, filamentous and, less commonly, vesicular ones. The filamentous type of grain consists 
of brown, septate and branched hyphae that may be slightly more swollen and thick towards the 
periphery of the colony (20, 26, 52). The vesicular type of grain, which is less common, has a cement-
like matrix in the cortex and a central area filled with numerous vesicles (6-14 IJm in diameter) and 
light-colored hyphae (58). Three types of tissue reactions around the grains have been described (26). 
In tissue reaction type 1, the grains are surrounded by three zones of inflammatory cells. An inner 
neutrophil zone immediately around the grain, an intermediate zone containing mainly macrophages, 
and an outer zone consisting of lymphocytes and plasma cells (20, 21, 26) (figure 4). 
Studies on the ultrastructure of M. mycetomatis showed an elaborate development of mesosomes as 
the most striking ultrastructural feature (29). In tissue sections, the hyphae show a thick cell wall, 
which becomes thicker in the periphery of the grain (20, 25, 36). It appears that excessive production 
of polysaccharides in the fungal cell wall renders the fungus less susceptible to the action of antifungal 
agents and more resistant to the host immune system, due to possible interference with leukocyte 
interaction with specifically recognized cell wall antigens (35, 36, 70). 
FUNGAL VIABILITY AND ANTIFUNGAL SUSCEPTIBILITY 
The vegetative cells of M. mycetomatis die rapidly in conditions of moist heat (e.g. 60oc for 30 
minutes) and are easily killed by 70% ethanoL Homogenized mycelia from fresh agar cultures survive 
well at 4°, -zoo and -sooc for at least several weeks (unpublished data). Little is known about the in 
vitro and in vivo susceptibility of the fungus to different antifungal agents, especially to the new 
generation azoles and the echinocandins. In the past, some reports described the effectiveness of 
ketoconazole in treating mycetoma patients. At least, ketoconazole therapy usually leads to some 
degree of improvement (14, 47). Few investigators described in vitro susceptibility testing results. 
Preliminary data have shown that the azoles were capable of inhibiting the growth of at least 50% of 
all M. mycetomatis strains included in the studies. Unfortunately, the in vivo activity spectrum of the 
azoles is often poor (6, 52, 69). Still, long term treatment with itraconazole seems to be the best 
therapeutic regimen at the present time. However, variable responses to itraconazole have also been 
described (6, 25, 52). Eumycetoma due to M. mycetomatis responds poorly to medical treatment with 
ketoconazole, especially in late, advanced cases, but lesions of patients under ketoconazole treatment 
remain localized and well encapsulated (25). 
No proper study using a standard protocol was carried out to evaluate the susceptibility of large 
numbers of M. mycetomatis clinical isolates. In general most of the investigators agree that early 
diagnosis followed by both surgical and chemotherapeutic treatment with appropriate antifungal 
agents results in the most successful outcome (4, 9, 27, 52). Mendez-Tovar eta!. have shown that 
progesteron can inhibit the growth of M. mycetomatis and Pyrenochaeta romeroi, which may 
contribute to the genuine sex difference in the incidence of mycetoma (9, 25, 52, 53). Addition of 
hormonal therapy to the standard chemotherapeutic regimen has not yet been evaluated in clinical 
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trials. 
M. MYCETOMA TIS IN ANIMALS 
In addition to man, natural mycetoma has also been reported in dogs, cats, horses, cows, goats and 
even in dolphins (1 0, 23, 33, 34, 38, 39, 42, 51, 54, 57, 60, 62, 63, 68). However, in contrast to 
actinomycetoma, the induction of eumycetoma in laboratory animals is very difficult. Many 
investigators reported reproducible animal models for bacterial mycetoma, but few investigators were 
successful in developing M. mycetomatis infection in small laboratory animals. Only sporadically, the 
characteristic black grains due to M. mycetomatis were reproduced in an animal model. This required 
inoculation of M. mycetomatis mixed with killed tubercle bacilli or the use of congenitally athymic nude 
mice. In immunocompetent mice such lesions were sometimes observed after repeated intraperitoneal 
inoculation (13, 45, 56). 
CONCLUSIONS 
In the endemic areas, mycetoma is a chronic infection affecting large numbers of people in the prime 
of their lives. The disease has, however, largely been ignored by public health authorities and 
neglected by the scientific community. Consequently, today, the infection remains difficult to diagnose, 
difficult to treat and still is a significant socio-economical factor to the susceptible population. Although 
M. mycetomatis is the major cause of mycetoma and has a world-wide distribution, little is known 
about the fungal ecology, the most susceptible hosts, and the host-pathogen interactions. Many 
questions still need to be answered. Are all isolates described by conventional morphological and 
physiological characteristics part of a single gene-species? If these are a single species, what is the 
correct taxonomic position in the fungal kingdom? What are the prime ecological niches of the fungus 
and which are the dominant routes of transmission leading to infections in humans? If the fungus 
resides in the soil, why was it essential never successfully recovered from this substrate? What are 
the in vitro and in vivo susceptibilities of the fungus to the common antifungal agents used for the 
treatment of patients? How does the immunopathology of infection develop? Can a reproducible 
animal model be designed? Can accurate, sensitive and specific serological or molecular techniques 
for species identification be developed? The present thesis describes investigations aimed at 
answering at least someof the question listed above. 
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SCOPE OF THE THESIS 
This first chapter provides a literature review on the tropical disease mycetoma. Literature resources 
were mainly the review articles, books and internet-accessible text published over the last 10 years. 
Special emphasis was placed on infections caused by M. mycetomatis. 
Chapter two describes the design of a molecular-diagnostic test for M. mycetomatis infections. 
Molecular analysis of the ribosomal gene operon of the fungus was performed and a species-specific 
PCR-mediated test was successfully developed. The diagnostic value of the PCR test has been 
validated with the help of a variety of clinical specimens. A report of two complicated mycetoma cases 
including successful molecular diagnostics is presented in Chapter three. The species identification of 
the causative organisms was performed with the newly developed molecular diagnostic test. 
Chapter four describes the utilization of the same molecular techniques in the study of the ecology of 
mycetoma causing agents. Using PCR, the environmental occurrence of M. mycetomatis in Sudan 
was studied. Molecular detection revealed the presence of fungal DNA in approximately one third of 
the soil samples from endemic areas, whereas culture-based searches were uniformly negative. 
Chapter five describes the phylogeny and typification of M. mycetomatis, with comparison to other 
agents of eumycetoma. This study resulted in molecular neotypification of M. mycetomatis and the 
identification of its most probable taxonomic position. 
Chapter six identifies the clonal behavior of clinical M. mycetomatis isolates. Large scale RAPD and 
PCR-RFLP typing of clinical isolates from Sudanese patients revealed that it is apparently impossible 
to distinguish DNA from a variety of clinical isolates of M. mycetomatis suggesting a recent 
evolutionary history or overall genome stability. 
Chapter seven describes a novel, reproducible mouse model for M. mycetomatis infection. Various 
routes of inoculation, various amounts of M. mycetomatis mycelium and different adjuvants were 
evaluated in mice, differing with respect to age, gender and immune status. 
Chapter eight describes a new protocol for determination of the Minimum Inhibitory Concentration 
(MIC) of different antifungal agents that may have therapeutic value against M. mycetomatis. The 
protocol based on the National Committee of Clinical Laboratory Standards guidelines M38-A was 
adapted for use with M. mycetomatis. The colorimetric assay (XTT test) was adapted and used to 
quantify the antifungal activity of the agents. Both assays were used to determine the in vitro activities 
of amphotericin B and itraconazole against a large number of M. mycetomatis clinical isolates. 
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ABSTRACT 
Madurel/a mycetomatis is the commonest cause of eumycetoma in Sudan and other countries in 
tropical Africa. Currently, early diagnosis of mycetoma is difficult. In attempting to improve the 
identification of M. mycetomatis and, consequently, the diagnosis of mycetoma, we have developed 
specific oligonucleotide PCR primers, based on the sequence of the internal transcribed spacer (ITS) 
regions spacing the genes encoding the fungal ribosomal RNAs. The ITS regions were amplified with 
universal primers and sequenced, and then two sets of species-specific primers were designed which 
specifically amplify parts of the ITS and the 5.8S ribosomal DNA gene. The new primers were tested for 
specificity with DNA isolated from human mycetoma lesions and DNA extracted from cultures of M. 
mycetomatis reference strains and related fungi as well as human DNA. To study the genetic variability 
of the ITS regions of M. mycetomatis, ITS am pi icons were obtained from 25 different clinical isolates and 
subjected to restriction fragment length polymorphism (RFLP) analysis with Cfol, Haelll, Mspl, Sau3AI, 
Rsal, and Spel restriction enzymes. RFLP analysis of the ITS region did not reveal even a single 
difference, indicating the homogeneity of the isolates analyzed during the current study. 
INTRODUCTION 
Mycetoma is a chronic granulomatous subcutaneous infection caused by true fungi (eumycetoma) or 
higher bacteria (actinomycetoma)(6, 14). The disease is endemic in tropical and subtropical areas and is 
the major mycological health problem in Sudan (6, 14). The majority of cases of mycetoma in Sudan are 
caused by Madurella mycetomatis. The pathogens involved are found in the environment in certain 
types of soil and are directly inoculated into the subcutaneous tissues, commonly in the foot, through 
minor trauma or a thorn prick (9, 14). Mycetoma has a prolonged, progressive, and indolent course and, 
if untreated, ultimately leads to destruction of deeper tissues and bone, resulting in deformity and 
disability which may necessitate amputation. The triad of a subcutaneous painless mass, sinuses, and 
grains discharged through the sinuses is the hallmark of mycetoma (6, 14). Diagnosis may be more 
difficult in early stages, especially prior to the appearance of the sinuses and grains. At this stage the 
disease may be difficult to distinguish from a variety of soft tissue tumors and granulomata (11, 22). 
Currently, the available diagnostic tools for mycetoma are few and have many limitations. Diagnosis is 
based on the identification of the grains in the discharge of the sinuses or biopsies from the lesions. 
Staining grains allows the identification of the causative organism, but this is of limited value in the 
differentiation of true fungi (18). Culture is always necessary for definitive diagnosis. However, culturing 
clinical specimens is cumbersome, time-consuming, prone to secondary bacterial contamination (1), 
always needs deep surgical biopsy under general anesthesia, and is not always practical or cost-
effective in areas of endemicity (18). Serodiagnosis is hampered by cross-reactivity among the multiple 
species of actinomycetes as well as by the lack of standardized antigen preparations(8, 19). 
Comparative studies of the nucleotide sequences of the rRNA genes provide a means for analyzing 
phylogenetic relationships over a wide range of taxonomic levels and to assist in the development of 
identification assays for fungal species (23). The small-subunit ribosomal rONA sequences evolve 
relatively slowly and are useful for studying distantly related organisms (23). The internal transcribed 
spacer (ITS) regions 1 and 2 can be amplified with the primers ITS5 and ITS4, which are located in the 
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conserved regions of the 18S and 28S genes, respectively. Together with the intergenic spacer of the 
nuclear rRNA repeat units, this region evolves faster and may vary among the different species within a 
genus or even among cells found in a single population (23). rONA sequences have been utilized by 
many investigators for the determination of species identity for a multitude of yeasts and fungi (2, 7, 10, 
12, 24). It has also been reported that ITS ribotyping is a simple method that can distinguish among 
most of the Saccharomyces species (16), and ITS sequences can differentiate between the closely 
related strains in the Trichophyton mentagrophytes complex (15). 
The aim of the present study was to supplement current diagnostic tools for mycetoma with the 
development of a species-specific PCR assay for identification of M. mycetomatis, based on the 
nucleotide sequence of the ITS regions in the rONA operon. The study also addressed the taxonomic 
position of the causative organisms and tested for the genetic variability of different M. mycetomatis 
isolates. 
MATERIALS AND METHODS 
Clinical specimens. Clinical specimens were collected from 48 consecutive patients presenting with 
black grain mycetoma at the Mycetoma Research Center, University of Khartoum, Sudan, during the 
period between November 1997 and August 1998. The patients were from different regions of the 
country. Following written consent from the patients, deep-excision biopsy specimens with visible grains 
were collected. 
Fungal isolates. For isolation of the fungus, some grains were collected from the biopsy specimens, 
washed twice in physiological saline containing 1% chloramphenicol, inoculated into Sabouraud's agar 
(Difco, Amsterdam, The Netherlands), and incubated at 37"C for 3 to 4 weeks. Potential M. mycetomatis 
cultures were identified morphologically, and the fungal mycelia were scraped and stored in 9% glycerol 
broth at·aooc and shipped to the Department of Medical Microbiology and Infectious Diseases, Erasmus 
University Medical Center Rotterdam, Rotterdam, The Netherlands. Control strains from related fungal 
species were obtained from the Centraalbureau voor Schimmelcultures, The Netherlands. The following 
eight reference strains were included: Madurella grisea CBS 331-50 and CBS 332-50, M. mycetomatis 
CBS 247.48 and CBS 868.95, Pyrenochaeta mackinnonii CBS 674.75, Pyrenochaeta romeri CBS 
252.60, Pyrenochaeta unguis-homini CBS 378.92, and Chaetosphaeronema larense CBS 640.73. 
DNA extraction and purification. Prior to DNA extraction the fungi were subcultured on Sabouraud's 
agar and incubated at 37"C for 3 weeks. The mycelia were scraped from the culture medium and 
homogenized with sterile pestles and a mortar. The homogenized mycelia were then snap frozen in 
liquid nitrogen, thawed and refrozen twice, and rehomogenized in 2 ml of lysis buffer containing 4 M 
guanidinium isothiocyanate, 0.1 M Tris-HCI (pH 6.4), 0.2 M EDTA, and 0.1% Triton X-100. The DNA was 
purified by Celite affinity chromatography (Janssen Pharmaceuticals, Beerse, Belgium) as described 
before (3). Two other DNA purification protocols were tested for the destruction of the cell wall of the 
fungus, using either lysis buffer with lyticase enzymes followed by proteinase K treatment (20) or 
cetyltrimethylammonium bromide (Janssen Pharmaceuticals) buffer at 56°C (21). 
PCR amplification. DNA extracts of 25 different M. mycetomatis isolates were amplified with primers 
ITS4 and ITS5 (23). The sequences of the two primers were 5'-TCCTCCGCTTATTGATATGC-3' and 5'-
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GGAAGTAAAAGTCGTAACAAGG-3', respectively. The PCRs were performed in 50-f.ll reaction 
volumes containing 0.2 U of Taq polymerase (Super Taq; HT Biotechnology, Cambridge, United 
Kingdom) and 5 ng of template DNA. Cycling was performed in a model 60 thermocycler (Biomed, 
Theres, Germany) with the following temperature trajectory: 40 cycles of alternating denaturation (94°C 
for 1 min), annealing of primers (58°C for 1 min), and enzymatic extension by the thermostable 
polymerase (72oc for 2 min). The PCR products were examined by electrophoresis in 1% agarose gels 
stained with ethidium bromide. 
Cloning, sequencing, and primer design. Amplimers obtained with primers ITS4 and ITS5 were 
cloned into the plasmid pCRII with the Topo-TA cloning kit (Invitrogen, Leek, The Netherlands) and 
sequenced commercially (Eurogentec, Seraing, Belgium). The sequences obtained were aligned, 
adjusted, and compared for homology with the sequences derived from other species and deposited in 
the various databases. Two potentially M. mycetomatis-specific sets of primers were designed (primers 
26.1A [5'-AATGAGTIGGGCTTIAACGG-3'] and 28.3A [5'-TCCCGGTAGTGTAGTGTCCCT-3'] and 
primers 26.1 B [5'-GCAACACGCCCTGGGCGA-3'] and 28.3B [5'-TCCGCGGGGCGTCCGCCGGA-3']). 
The newly designed primers were tested for sensitivity and specificity with a PCR protocol that was 
identical to the one described above except that the extension step was shortened to 1 min. 
Detection of ITS polymorphisms. Restriction fragment length polymorphism (RFLP) in the M. 
mycetomatis ITS regions was assessed by analysis of the PCR products generated by primers ITS4 and 
ITS5 with Cfol, Mspl, Haelll, Rsal, Sau3A, and Spel restriction enzymes (Boehringer-Mannheim, 
Mannheim, Germany). The enzymes were used as recommended by the manufacturer. RFLP was 
determined by electrophoresis in 3% Nusieve GTG agarose gels (Biozym, Landgraaf, The Netherlands). 
Nucleotide sequence accession number. The sequence of the M. mycetomatis ITS region has been 
deposited in GenBank under accession no AF162133. 
RESULTS 
From the 48 patients, 45 isolates were successfully cultured. Of these 45 isolates, only 25 survived 
storage at -80°C and transportation from the Sudan to The Netherlands. DNA isolation from fungal 
mycelia was initially performed in a comparative fashion. The three different protocols used for DNA 
purification gave virtually the same yield of DNA. 
The amplified DNA fragments of the ITS regions (with ITS4 and ITS5 primers) of M. mycetomatis and 
the control strains were found to be between 600 and 1 ,200 bp in length (Figure 1 ). Note that there 
appears to be a small difference in length when the amplicons obtained for the two M. mycetomatis 
reference strains are compared. PCR products of identical size (approximately 630 bp) were obtained 
when DNA extracted from the clinical isolates of M. mycetomatis was amplified (result not shown). The 
size of this fragment equaled that obtained forM. mycetomatis CBS 247.48. Cloning and sequencing 
of this type of ITS fragment for M. mycetomatis revealed that the fragment was 624 bp in length, which 
includes the ITS4 and ITS5 primers. The potentially species-specific primer sets 26.1A and 28.3A and 
26.1B and 28.3B were found to be specific forM. mycetomatis DNA (Figure 1). When the 26.1A-28.3A 
combination was used, a fragment of about 420 bp was synthesized, which is in agreement with 
expectations on the basis of the ITS nucleotide sequence. Similar-sized fragments were obtained as 
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well when DNA isolated from the clinical strains was used as a template (n = 25). The primers did not 
amplify human DNA. 
When the sequences determined for the ITS regions of two different M. mycetomatis isolates were 
compared, they were found to be identical with only minor ambiguities in two nucleotide positions. 
Running the M. mycetomatis spacer sequence through the GenBank data depository did not highlight 
any closely related sequence homologues from other fungal species. Ranking of homologous 
sequences indicated that the ITS sequence as determined for a nonspeciated isolate from the genus 
Phialophora came closest to the Madurel/a sequence. However, the homology appeared to be mainly 
restricted to the ribosomal gene sequences. In ITS1 several mutations were documented, whereas in 
ITS2 a 11 a-nucleotide stretch showing no significant homology was encountered. Consequently, the 
generation of informative parsimony trees will have to await the determination of ITS sequences for 
more closely related fungal species, such as the ones used in the control panel described above. 
The RFLP pattern generated by six different restriction enzymes produced banding profiles that were 
in full agreement with the nucleotide sequence. The RFLP patterns generated for the control species 
were clearly different (Figure 2). The two M. grisea isolates could not be discriminated but clearly 
differed from the M. mycetomatis isolates. Furthermore, the three species of Pyrenochaeta could be 
distinguished, since P. romeri and P. unguis-homini differed only in a single Haelll site (Figure 2, 
bottom panel). The RFLP pattern obtained for M. mycetomatis (CBS 247.48) matched the RFLP 
pattern of the clinical isolates. In all assays, M. mycetomatis (CBS 868.95) showed profiles completely 
different from those of all other M. mycetomatis strains, raising doubts about the species status of this 
isolate (see Discussion). 
M 1 2 3 4 5 6 7 8 9 1 0 11 12 13 14 15 16 17 18 19 20 M 
600-
-600 
Figure 1. PCR amplification of the ITS for M. mycetomatis and related species. Lanes 1 to 8 show the 
amplicons obtained by using the universal primers ITS4 and ITS5. DNAs from the following species 
were amplified: M. grisea CBS331-50 (lane 1) and CBS 332-50 (lane 2), M. mycetomatis CBS 247.48 
(lane 3) and CBS 868.95 (lane 4), P. mackinnonii CBS 674.75 (lane 5), P. romeri CBS 252.60 (lane 6), 
P. unguis-homini CBS 378.92 (lane 7), and C. larense CBS 640.73 (lane 8). In lanes 9 to 16 PCR 
results obtained with the primer combination 26.1A and 28.3A are displayed; the strains are ordered 
similarly from left to right. Note that only M. mycetomatis CBS 247.48 yielded a positive signal. Lanes 
17 to 19 show the representative PCR products obtained for all of the clinical M. mycetomatis isolates. 
Lane 20 contains the negative PCR control. On the left and right the molecular size of the intensely 
fluorescing 600-bp-long fragment in the 100-bp ladder is indicated. 
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DISCUSSION 
Successful medical treatment or surgical excision of mycetoma lesions depends on the accurate 
diagnosis of the type of mycetoma and determination of the extent of the lesion. The latter is often 
difficult preoperatively, since the available diagnostic tools are not sensitive or specific (6, 14). In 
addition to the laboratory procedures for staining, cultivation, and serology already in use for detection 
of M. mycetomatis, aspiration cytology of mycetoma was recently described, but in the absence of 
grains the test is of little value (5). Histopathological examination is useful, but it carries a substantial 
risk of spreading mycetoma, since a deep surgical biopsy is always required (2). Furthermore, it is less 
reliable than a positive culture (18). Also, with histopathology it is not possible to differentiate among 
the different clinically important species, such as M. mycetomatis and M. grisea (13). In conclusion, no 
simple test is currently available for the diagnosis of mycetoma, other than clinical assessment and the 
invasive procedure of surgical biopsy. Furthermore, assessment of response to treatment is difficult, 
as is the prediction of cure or relapse in the absence of a reliable diagnostic test. 
Our results showed that M. mycetomatis can be easily isolated from clinical specimens, but its survival 
in the glycerol stock cultures is quite poor. This explains the lack of available archival stocks of M. 
mycetomatis, which has been described previously (17). It appeared that the protocol employing 
freeze-thaw cycles in combination with the guanidinium lysis procedure was most convenient for DNA 
isolation in our laboratory setting. It should be mentioned that the yield equaled that of the other 
procedures, implying that the alternative procedures can be used as effectively. 
Here we present the first nucleotide sequence information for the fungal species M. mycetomatis. 
RFLP analyses of the ITS region for which the primary structure was elucidated demonstrate a high 
degree of homogeneity among clinical isolates of M. mycetomatis. The sizes of the different restriction 
fragments generated precisely match expectations based on simple analysis of the primary structure of 
the ITS region (analysis not shown). These results seem to be in conflict with an earlier supposition by 
De Hoog eta!. (4) that agents of mycetoma would be highly diverse. The present data indicate that 
mycetomata are caused by endemic species, possibly with a limited geographical distribution or given 
the identity of the Caribbean strain with the Sudanese isolates at least a local preponderance. 
Imported cases of mycetoma, such as those in The Netherlands (4), comprise cases from diverse 
localities and hence are likely to show a higher species diversity. 
Figure 2. RFLP analysis of the ITS amplicons obtained for M. mycetomatis and related species. Lanes 1 
to 8 show the results obtained for M. grisea CBS331-50 (lane 1) and CBS 332-50 (lane 2), M. 
mycetomatis CBS 247.48 (lane 3) and CBS 868.95 (lane 4), P. mackinnonii CBS 674.75 (lane 5), P. 
romeri CBS 252.60 (lane 6), P. unguis-homini CBS 378.92 (lane 7), and C. /arense CBS 640.73 (lane 8). 
The three panels were generated with the restriction enzymes indicated (Cfo/, Msp/, Hae/11). Lanes 9 to 
16 show the results obtained for eight of the clinical M. mycetomatis isolates, indicating the high degree 
of ITS homogeneity. Lanes M contain the 100-bp size marker ladder; the position of the 600-bp-long 
fragment is indicated. 
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Indeed, the M. mycetomatis-like strains from The Netherlands proved to represent a very different 
taxon. The geographical origin of the patients is thus an important factor in the anamnesis of cases of 
mycetoma. Several potential explanations for the genetic homogeneity among the clinical isolates of 
M. mycetomatis can be considered: the entire species may be clonal, there may be a type of M. 
mycetomatis that has spread through Sudan, or there may be an intimate link between infection and 
fungal type. The fact that preliminary randomly amplified polymorphic DNA studies have demonstrated 
at least a certain degree of genetic heterogeneity in regions other than the ribosomal operons indicates 
that at present this question cannot be answered and that future studies, involving additional, 
geographically diverse strains of M. mycetomatis, are mandatory. 
On the basis of the noncoding ITS regions, we designed PCR primers for the identification of M. 
mycetomatis, the major cause of eumycetoma in the Sudan. The differentiation of the two clinically 
relevant Madurella species is feasible with our newly described assay in a manner that could not be 
achieved by currently used immunological techniques, such as Western blotting (25). By using the 
newly designed primers, future diagnosis of eumycetoma caused by M. mycetomatis may be quicker 
and simpler, even in the early stages of the infection. We have already been able to detectfungal DNA 
in biopsy specimens of mycetoma lesions, but serum samples or regional lymph node biopsy 
specimens still require additional testing (preliminary observations). To conclude, all M. mycetomatis 
organisms isolated during the course of this study belong to a single species. In addition, the clinical 
value of the newly designed PCR RFLP test for the identification of M. mycetomatis can now be 
assessed for early case detection, assessment of subclinical infections, and follow-up of patients and 
for determination of cure or relapse. 
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ABSTRACT 
We describe two cases of eumycetoma in the legs. The infections could not be adequately diagnosed by 
classical mycology, but the causative agents were successfully identified as Madurella mycetomatis by 
species-specific PCR and DNA sequencing. 
INTRODUCTION 
Tropical mycoses are often imported into Western countries due to the increasing number of immigrants. 
This challenges the medical microbiology laboratory since correct diagnosis is usually difficult. Mycetoma is 
a good example of an infection which is complicated to diagnose, especially because of its large number of 
possible causative agents (6). De Hoog eta/. (4), for instance, reviewed eight cases imported in The 
Netherlands, in which only one out of seven isolates, Actinomadura madurae, belonged to a commonly 
known agent of mycetoma. The other isolates either belonged to very rare species, such as Phialophora 
cyanescens, or were not identifiable at all. 
In this report, we show how molecular techniques in combination with an updated taxonomy can be utilized 
to solve these diagnostic problems. We discuss two mycetoma cases which with the help of PCR and DNA 
sequencing, were ultimately shown to be caused by Madurella mycetomatis. 
THE FIRST CASE 
A 39-year-old man, born and living in Mali. This patient was first seen on the 2"ct of December 2000 at 
Saint Joseph Hospital in Paris, France. The patient was admitted with a fistulated infection of the left 
ankle, showing multiple draining sinuses. Radiographs identified a lytic lesion in the distal part 
associated with the fibula. The patient had a history of excision of an abscess containing black grains 
near the knee joint 3 or 4 years ago in Mali. At that time, he received co-trimoxazole for several 
months, without apparent improvement. The abscess, which appeared to be a mycetoma lesion, did 
not heal. Apparently, either the excision was incomplete or the patient developed a re-infection. One 
week after admission to the hospital, the patients underwent massive excision of soft tissues and 
infected bone. Numerous black grains were seen in the surgical specimens, which were hard in 
consistency and irregular in size and in shape. Clinical material was sent to St Joseph Hospital=s 
microbiology laboratory. Direct microscopical examination of the grains revealed fungal hyphae with 
some swollen cells. Prior to culture, the grains were washed in sterile water and then seeded directly 
onto Sabouraud dextrose agar and Chocolate blood agar and incubated at 30° and 3rc. The growth 
was better at 3rC. After a few days of incubation, Streptococcus pyogenes (group A) was isolated and 
4 to 5 days later, a slow-growing fungus producing brown diffusible pigments was recovered. The 
fungus showed better and more rapid growth on chocolate agar. To enhance sporulation, the fungus 
was subcultured on Soil extract agar and incubated at 25°C for eight weeks. The culture remained 
sterile, and no spores or conidia were seen (Figure 1-A). After eight weeks of incubation, still only 
vegetative hyphae with some swollen chlamydospore-like cells were seen. The isolated fungus could 
not be accurately identified to the species level. No additional pathological investigation was performed 
for this patient. The case was diagnosed as eumycetoma and managed with several surgical 
debridements combined with chemotherapy. Three weeks after the initial excision muscle flap 
coverage and skin grafting was performed. The patient received oral itraconazole and amoxicillin for 6 
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weeks followed by oral amoxicillin and itraconazole for 14 weeks, after which the medical treatment 
was stopped. The patient was followed for two more months. No evidence of recurrence of infection 
was observed at the last follow up, and since then, the patient did not return for follow up. 
Figure 1: A· Direct microscopy of 8 weeks cultures of M. mycetomatis (P-1) on Soil extract agar. Only 
vegetative hyphae with some chlamydospores-like cells (arrows) were seen. Due to the absence of spores, 
conidia, or specialized conidiogenesis cells or conidiophores, such preparation has a little diagnostic 
value. B- M. mycetomatis specific PCR for species identification using primers 26.1A and 28.3A. Lanes 1 
and 6 containing 100 b.p. molecular weight marker. Lanes 2-5 show the PCR amp !icons of P-1, P2, 
positive control and negative control respectively. Both P-1 and P-2 were positive. 
THE SECOND CASE 
A 45-year-old man born in Mali, living in Paris (France) for more than 20 years, but traveling to Mali 
regularly, presented at the Croix Saint Simon Hospital, on January 3, 2001 at the Orthopedic Department. 
The patient was complaining of rheumatic arthritis in the left knee joint. During examination the orthopedic 
surgeon discovered a large subcutaneous indolent mass in the inner part of the right knee (Figure 2-A). 
There were no sinuses and consequently no discharge. Magnetic resonance images showed a soft tissue 
mass without any bone or joint involvements (Figure 2-B). The subcutaneous mass initiated gradually and 
grew slowly over the past 3 years. The patient did not recall any trauma, puncture or wound at the site of 
the infection. Complete surgical excision was performed and the entire biopsy was sent for microbiological 
and pathological examination (Figure 2-C). Direct examination and cultures were done in St Joseph 
Hospital=s microbiology laboratory, while pathological examinations were done by Dr. Michel Forest, 
Cochin Hospital, Paris, France. The lesion was well encapsulated, and it appeared to have been excised 
completely. The bone and the knee joint were healthy and intact. The lesion measured more than 15 
centimeters in length and consisted of dense fibrous tissue containing multiple cavities full of black grains 
and bloody puss (Figure 2- E and F). Black grains were hard in consistency, and had different shapes and 
sizes. Microscopically, the grains showed hyphae and swollen cells. Pure filamentous fungus was isolated 
from the grains. The cultures were done exactly the same as described for the first case. The fungus also 
showed better growth at 37"C than at 30°C. Better and rapid growth was obtained on chocolate agar after 
3 to 4 days (Figure 2-D). The fungus was subcultured on soil extract agar for identification. Good growth 
was obtained after 2-3 weeks, but again fungal cultures remained sterile, and accurate identification was 
impossible. To avoid recurrence, the patient was started on oral itraconazole (400 mg two times per day) 
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immediately after surgery. Due to digestive problems, the dose was reduced to 300 mg (two times per 
day). The patient continued on treatment and was seen after three months, when the medical treatment 
was discontinued. The patient was seen once again one month later and again after one year. He cured 
completely. 
MOLECULAR MYCOLOGY 
Although the infections were correctly diagnosed from the clinical prospective as being a case of 
eumycetoma, the identification of the causative organisms remained a problem. For this reason the two 
fungal isolates were sent to the Department of Medical Microbiology and Infectious Diseases, Erasmus 
MC, Rotterdam, The Netherlands for identification. The two isolates were coded P-1 and P-2 and 
subcultured into Sabouraud dextrose agar and incubated at 37°C for 3 weeks. Identification was attempted 
based on the keys proposed by de Hoog eta/ {5). The cultures consisted of thallus built of regularly septate 
hyphae without clamp connections and fruit bodies. Both cultures were sterile, dark-brownish in color and 
producing black diffusible pigments. Morphologically, the cultures were similar to the known agent of 
eumycetoma M. mycetomatis. To confirm this presumptive identification, molecular verification was 
pursued. 
Three-weeks cultures, incubated at 37°C, were subjected to DNA isolation. A previously identified M. 
mycetomatis clinical isolate was included as a positive control. The fungal material was excised from the 
agar and transferred into 6 ml of a 0,9% NaCI solution. The material was homogenized by sonication for 2 
minutes at 30 micron (Soniprep 150, Beun de Ronde, Abcoude, The Netherlands) to fully disrupt the 
mycelium. Five hundred J.JI of this suspension was taken and DNA was isolated according to the DNA 
extraction method described by Boom eta/ (3). The extracted DNA was tested directly by M. mycetomatis 
species-specific PCR as has been described before (1 ). The PCR reaction mixture without template DNA 
was used as a negative control. The PCR reaction was performed in a model 60 Thermocycler (Biomed, 
Theres, Germany). The PCR products were analyzed by electrophoresis on 1% agarose gels and the 
specific, 424 base pair fragments were seen for both fungal isolates, which exactly matched the positive 
control. No amplicons were seen in the negative control lane (Figure 1-B). 
PCR primer sequences were based on the Internal Transcribed Spacer of M. mycetomatis ribosomal 
genes, and were previously shown to react only with M. mycetomatis DNA. The resulting PCR is able to 
distinguish M. mycetomatis from the other black grain mycetoma agents including its close relative M. 
grisea (1 ). Based on this PCR result, the two isolates were presumptively identified as M. mycetomatis. In 
order to have further confirmation and to study the phylogenetic relationship with other M. mycetomatis 
isolates from different geographical origins, the two isolates were subjected to ITS sequencing using 
primers ITS1 and ITS4 (9). Sequencing reactions were carried out in 10 J.JI volumes containing 15-50 ng of 
the fungal DNA, 4 pmol sequencing primer and 4 J.JI Big Dye Mix (Applied Biosysterns, Nieuwerkerk a. d. 
ljssel, The Netherlands). The DNA products were analysed on an ABI Prism® 310 Genetic analyzer 
(Applied Biosystems). The sequences were adjusted using SeqMan software (DNAStar, Madison, 
Wisconsin, USA) and aligned using BioNurnerics (Applied Maths, Kortrijk, Belgium). The sequences were 
directly compared with all entries of the CBS database. 
The P-1 and P-2 sequences showed over 99% similarity with those of theM. mycetomatis reference strain 
CBS 247.48, the M. mycetomatis reference strain CBS 110087, the new-type strain of M. mycetomatis 
(CBS 109801, isolated from Sudan) and with three other clinical isolates from Sudan (6). Thus, PCR and 
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sequencing confirmed that the causative agent in both patients was M. mycetomatis, belonging to the order 
of the Sordariales in the class Ascomycetes. M. mycetomatis is the most prevalent etiological agent of 
black grain eumycetoma (8), which is a chronic granulomatous infection of subcutaneous and deep tissues 
(2). In some endemic areas, this fungus is responsible of more than 70% of all mycetoma infections, 
although microbiological identification is often difficult or impossible (2). 
Figure 2: A- Massive subcutaneous mass involving the inner part of the right ness. B- T1- weighted 
magnetic resonance image after gadolinium injection showing massive soft tissue mass. Bone and knee 
joint are healthy and not involved. C- During surgical excision, the lesion was well-encapsulated, and it 
was excised completely. Note the massive lesion, which measure about 16 centimeters. D- Four days 
culture of the black grains on Chocolate blood agar. The fungus starts as white mycelium and later become 
olivaceous or brown. E- The lesion was consisting of dense fibrous tissues containing multiples cavities full 
thick exudates containing pus, blood and grains. F- Gomeri Grocot staining showing fungal grain 
surrounded by inflammatory cells. You can see clearly the fungal hyphae growing toward the periphery of 
the grain. 
CONCLUDING REMARKS 
The two patients were clinically diagnosed as suffering from eumycetoma, and both were treated with a 
combination of anti-mycotics and surgery. Unfortunately, the follow-up of the first case was rather short and 
it was impossible to assess the patient=s ultimate response to the medical treatment. Since fungal 
mycetoma is always difficult to treat and the chance of recurrence of the infection is quite high, especially 
when only surgery is involved, follow-up is deemed important (2, 8). For the second patient the situation 
was better. The treatment was stopped rather early, but since his lesion was nicely capsulated, the patient 
was seen after one and a half year and the knee was still healthy. Both patients were originally from Mali, 
which is located in the mycetoma endemic zone in the African continent. However, few reports have 
appeared in the literature describing the disease in Mali. The most recent report of 1996, written by Mahe 
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eta/, showed that eumycetoma was apparently caused mainly by M. mycetomatis, but this author did not 
use molecular technology to really confirm this hypothesis (7). Our patients from Mali were living in France, 
but their clinical history showed that they most likely acquired the infection during their stay in Mali. 
In fact most cases of mycetoma that are imported into the West are not easily diagnosed. The clinical 
picture of a subcutaneous mass, sinuses and discharge containing grains is diagnostic for mycetoma. 
However, a large number of etiological agents are able to cause this infection, and they all produce 
almost similar clinical condition. In addition, these microorganisms show poor morphological 
differentiation and usually present as sterile hyphae, this makes their identification rather difficult if not, 
impossible (4,6). 
Molecular taxonomy and PCR now, for the first time, facilitate detailed studies on the incidence of 
mycetoma infection caused by M. mycetomatis and its physiologically similar agents. 
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ABSTRACT 
Madurella mycetomatis is the main causative agent of human eumycetoma, a severe debilitating disease 
endemic in Sudan. It has been suggested that eumycetoma has a soil-borne or thorn prick-mediated origin. 
For this reason, efforts were undertaken to culture M. mycetomatis from soil samples (n = 43) and thorn 
collections (n = 35) derived from areas in which it is endemic. However, ribosomal sequencing data 
revealed that the black fungi obtained all belonged to other fungal species. In addition, we performed PCR-
rnediated detection followed by restriction fragment length polymorphism (RFLP) analysis for the 
identification of M. mycetomatis DNA from the environmental samples as well as biopsies from patients with 
mycetoma. In the case of the Sudanese soil samples, 17 out of 74 (23%) samples were positive forM. 
mycetomatis DNA. Among the thorn collections, 1 out of 22 (5%) was positive in the PCR. All PCR RFLP 
patterns clearly indicated the presence of M. mycetomatis. In contrast, 15 Dutch and English control soil 
samples were all negative. Clinically and environmentally obtained fungal PCR products share the same 
PCR RFLP patterns, suggesting identity, at least at the species level. These observations support the 
hypothesis that eumycetoma is primarily environmentally acquired and suggest that M. mycetomatis needs 
special conditions for growth, as direct isolation from the environment seems to be impossible. 
INTRODUCTION 
Eumycetoma is a subcutaneous fungal infection in which the etiological agent occurs in the form of more or 
less compact mycelial grains. The immune response is a granulomatous foreign body reaction 
characterized by impressive local necrosis and the formation of extensive fistula (8, 9,18). Areas where 
eumycetoma is endemic are arid and hot climate zones with limited rainfall. A genuine "mycetoma belt" is 
found in tropical and subtropical regions, with foci in southern India, Somalia, Senegal, Argentina, and 
Sudan (12, 17). Cases are particularly common in Sudan, where, for example, Abbott (1) reported 1 ,231 
cases in a 2.5-year period. The main causative agent of eumycetorna in Sudan is Madurella mycetomatis 
(4, 15). The disorder is supposed to originate from traumatic inoculation of plant material or soil 
contaminated by these fungi. Abbott ( 1) noted a history of thorn pricks in 10 out of 62 cases of mycetoma, 
and in two of these, there were actually thorns found embedded in tissue. Basset et al. (3) reported two 
cases with thorns inside lesions from which only non-Madurella fungi could be isolated. It is unlikely that M. 
mycetomatis represents a primary pathogen for humans. Rather, the fungi involved probably are 
saprophytes, which are able to tolerate uncharacteristic conditions when inoculated by coincidence. 
However, direct evidence for this hypothesis is still lacking. Thirumalachar and Padhye (22) were barely 
able to recover M. mycetomatis from soil. This is rather unexpected for a saprophytic fungus. 
The present paper reports efforts to find M. mycetomatis in the environment in Sudan. Isolating fungi by 
culturing soils and thorns, which are preconditioned for traumatic inoculation, was attempted. Isolated 
strains were compared to patient strains from Sudan that were identified as M. mycetomatis (2). 
Environmental fungal isolates with a colony appearance resembling that of Madurel/a were identified and 
compared by molecular methods. In addition, direct PCR-mediated testing of environmental material was 
performed. 
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MATERIALS AND METHODS 
Strains and culture conditions. Strains presented in the current study are listed in Table 1. Sudanese 
Madurella strains used for comparison were those of Ahmed et al. (2), isolated by direct culture of black 
grains obtained from deep biopsies of patient lesions at the Mycetoma Research Center, Khartoum, Sudan. 
They were maintained on malt extract agar (MEA) slants at 24 oc and transferred to fresh tubes regularly to 
preserve viability. Reference strains, selected from genera being reported as agents of eumycetoma, were 
retrieved from the collection of the Centraalbureau voor Schimmelcultures (Utrecht, The Netherlands). 
Cultivation of environmental pigmented fungi. Strains were cultured from soil and thorn samples 
collected in the Gezira area along the Blue Nile southeast of Khartoum, Sudan (Figure 1 ). From 43 samples 
(up to 20 em in depth), 4 g of soil was suspended in 30 ml of sterile 0.9% saline by high-speed vortexing for 
5 min. After settling, the supernatant was diluted 1:5 and 1:50 for inoculation of two or three MEA culture 
plates with 0.5 ml of the suspension. 
Red 
Sea 
Figure 1: Detailed map of 
the region in Sudan where 
the thorns were collected 
and the soil was sampled. 
Main sampling sites were in 
the encircled region 
compnsmg the region 
southeastern to Khartoum 
(Wad Madani and Sinnar). 
Other regions where 
mycetoma is highly endemic 
are highlighted by the elliptic 
red-dot regions. The red 
bars indicate the boundaries 
of the Sudanese mycetoma 
belt. 
Thirty-five thorn samples were collected and divided into two groups: fresh ones from green bushes (15 
samples) and old ones lying on the ground or from old dry bushes (20 samples). Thorns primarily derived 
from the abundant species Acacia mallifera. Two or more thorns, depending on their size, were crushed in 
2 ml of 0.9% sodium chloride solution. Two dilutions were made to inoculate two plates each (fresh thorns, 
1:1 and 1:1 0; old thorns, 1:10 and 1:1 00). To decrease the number of contaminants in the case of several 
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samples, two thorns were briefly rubbed with a cotton swab with 70% ethanol before dilution (fresh thorns, 
1 :1; old thorns, 1:1 0) and used to inoculate two plates. Aliquots of 0.5 ml were used per culture plate with 
Sabouraud's dextrose agar (SDA) containing 100 mg of chloramphenicol/liter. Plates were incubated at 
3roC and checked for appropriate colonies at 3-day intervals. Strains with a colony appearance similar to 
that of M. mycetoma tis and exuding a rusty brown, diffusible pigment into the agar were selected (16, 22). 
DNA isolation of fungi isolated from soil. For DNA extraction, about 1 cm2 of mycelium was transferred 
to a 2:1 mixture of silica gel and Celite 545 with 300 iJI of cetyltrimethylamrnonium bromide (CTAB) buffer 
(200 mM Tris-HCI, [pH 7.5], 200 mM Na-EDTA, 8.2% NaCI, 2% CTAB). The material was ground with a 
micro-pestle (Eppendorf). After adding an additional 200 iJI of CTAB buffer and vigorous shaking, the 
sample was incubated for 10 min at 65°C in a water bath. An equal volume of chloroform was added, 
vortexed briefly, and centrifuged for 5 min at 14,000 rpm (modei5915C centrifuge; Eppendorf, Hamburg, 
Germany). After transferring the aqueous supernatant to a new Eppendorf tube, 2 volumes (;:::;800 iJI) of 
96% ethanol were added and mixed gently. DNA was precipitated at -2ooc for at least 30 min. The pellet, 
obtained by centrifugation, was washed twice with 500 iJI of 70% ethanol. DNA was dried overnight at room 
temperature and suspended in 97.5 iJI of TE buffer (1 0 mM Tris, 10 mM Na-EDTA, pH 8.0) with 2.5 iJI of 
RNase solution (200 U of pancreatic RNase Aim I in 0.01 M sodium acetate). Samples were incubated for 5 
to 30 min at 3roC and stored at -20°C. 
Ribosomal PCR and sequencing for identification of soil organisms. DNA samples isolated from 
unknown strains isolated from soil or thorns was analyzed by a general primer-mediated ribsomal PCR test. 
The rONA internal transcribed spacer (ITS) domain was amplified with primers V9G and LS266 (11 ). Other 
primer combinations (V9G/ITS4, LS266/ITS5) were used in case of negative results. The near-complete 
SSU rONA gene was amplified with primers NS1 and NS24. Of several programs used, optimal results 
were obtained with the following: 94°C for 5 min followed by 30 cycles of 94°C for 1 min, 48°C for 1 min, 
and 72oC for 2 min, followed by 72°C for 3 min. One unit of Super-Taq polymerase (Sphaero Q, Leiden, 
The Netherlands) was used for a 50-iJI reaction mixture with 2 iJI of DNA. In some cases, 6% 
dimethylsulfoxide (Merck, Darmstadt, Germany) was added. Am pi icons were purified using the GFX PCR 
DNA and Gel Band Purification Kit according to the manufacturer's instructions (Amersham Pharmacia, 
Roosendaal, The Netherlands). Concentrations of amplicons were estimated by comparison with a marker 
(SmartLadder; Eurogentec, Seraing, Belgium) on a 1% agarose gel. 
The sequencing reactions were carried out with 15 to 50 ng ofDNA for a 1 0-iJI reaction mixture, including 4 
pmol of primer and 4 iJI of Big Dye RR Mix (Applied Biosystems) using primers ITS4 and ITS1 (ITS domain) 
or Oli1, Oli5, Oli9-11, Oli13, and Oli14 (reference 21 and Table 2) and NS24 (SSU gene)with 25 cycles, as 
follows: 96°C for 10 s, 50oc for 5 s, and 60°C for 4 min. Sequence reaction products were analyzed on an 
automated capillary sequencer (ABI, Gouda, The Netherlands). The sequences were adjusted using 
Seq Man of Lasergene software (DNASTAR Inc., Madison, Wis.) and analyzed using BioNumerics (Applied 
Maths, Kortrijk, Belgium). Sequences were compared to a set of dedicated sequences available at CBS 
(ITS fragment ITS 1 +2, including 5.8S and the nearly complete SSU). Sequences of putative agents of 
eumycetoma were included (e.g., Acremoniumspp., Chaetomium, Neotestudina spp., Pseudal/escheria 
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spp., Bipolaris, Leptosphaeria, and Madurelfa spp.). The sequences alignment was considered confident 
when less than a 10% difference was observed. In case no match was found, sequences were run against 
the EMBL databank using BLAST. 
Processing of soil and thorn samples for direct DNA testing. Two grams of soil (74 Sudanese 
samples, 14 Dutch controls, and 1 United Kingdom control) or four or five thorns (n = 22) were suspended 
in 5 or 2 ml of samples, sterile physiological saline containing 2% sodium dodecyl sulfate (SDS) (Merck, 
Darmstadt, Germany) and 5 mg of proteinase K (Merck). The samples were incubated at room temperature 
on a horizontal shaker for 10 min and then incubated at 37"C (1 h). One milliliter of the clear upper layer of 
the suspensions was extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1 ). The 
DNA was precipitated from the aqueous layer with cold absolute ethanol (Merck). The pellet was washed 
once with 70% ethanol, air dried, and dissolved in 100 iJI of sterile distilled water. This crude extract was 
further purified with the QIAmp Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's 
recommendations. The extracted DNA was then immediately tested by PCR. 
PCR RFLP analysis of DNA extracted from thorns and soil samples. This analysis aimed at the broad-
spectrum amplification of fungal DNA, followed by an M. mycetomatis-specific nested PCR. In the first 
PCR, ITS4 and ITSS primers were used: 5'-TCCTCCGCTTATTGATATGC-3' and 5'-
GGAAGTAAAAGTCGTAACAAGG-3', respectively (23). For the nested PCR, M. mycetomatis specific 
primers 26.1A (5'-AA TGAGTTGGGCTTT AACGG-3)and (AA TGAGTTGGGCTTT AACGG-3) and 28.3A (5'-
TCCCGGTAGT'GTAGTGT-CCCT-3) were employed (2). The PCRs were performed in 50-IJI reaction 
volumes containing 0.2 U of SuperTaq polymerase (HT Biotech, Cambridge, United Kingdom), PCR buffer, 
deoxynucleotide triphosphate mix, 50 pmol of each primer, and 10 iJI of extracted DNA (approximately 100 
ng of DNA) in the first PCR round and 5 IJI of the amplified material in the nested PCR. Cycling was 
performed in a model 60 thermocycler (Biomed, Theres, Germany) for 40 cycles (94 oc for 1 min, ssoc for 1 
min, 72oC for 3 min). PCR products were examined by electrophoresis in 1% agarose gels containing 
ethidium bromide (0.31-Jg/ml). The electrophoresis was carried out in O.Sx Tris-borate-EDTA (TBE) buffer at 
a constant current of 100 rnA for 1 h. Restriction fragment length polymorphism (RFLP) in the M. 
mycetomatis ITS regions was studied by analysis of the PCR products generated by primers 26.1 A and 
28.3A by cleavage with Cfol, Mspl (BoehringerMannheim GmbH, Mannheim, Germany), and Haelll (New 
England Biolabs, Boston, Mass.) restriction enzymes. The restriction enzymes were used as recommended 
by the manufacturers. Fifteen microliters of PCR product was incubated overnight at 37°C with the 
restriction enzyme mixtures, which contained enzyme's buffer and 5 U of each enzyme per reaction. RFLP 
was determined by electrophoresis in 3% Nusieve GTG agarose gels (FMC Bioproducts, Rockville, Md.). 
The electrophoresis was performed in O.Sx TBE buffer at a constant current of 100 rnA for 3 h. 
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Table 1: Survey of strains 
Strain Species Source Similarity with reference M 
mycetomatis 
rRNAse . a 
Reference strains 
CBS 247.48 M mycetomatis United States (Gammel) 100% 
CBS 201.38 Madurel/a sp. 1 Indonesia Confident alignmentb 
CBS 248.48 Madurella sp. 1 New Mexico Confident alignment 
CBS 217.55 Madurella sp. 1 Argentina Confident alignment 
CBS 216.29 Madurella sp. 2 Italy Distantly related 
Clinical isolates 
DH11849 M mycetomatis Sudan, patient 0-bp difference 
DH11850 M mycetomatis Sudan, patient 0-bp difference 
DH11854 M mycetomatis Sudan, patient 0-bp difference 
P2 M mycetomatis Sudan, patient 1-bp difference 
DH11853 M. mycetomatis Sudan, patient 2-bp difference 
DH11862 M mycetomatis Sudan, patient 3-bp difference 
Environmental isolates 
DH11963 Exserohilum mcginnisii Sudan, soil Non relevant 
dH11959 Bipo/aris papendorfi Sudan, soil Non relevant 
dH11984 Bipolaris spicifera Sudan, soil Non relevant 
4 U/ospora bi/grami Sudan, thorn Nonrelevant 
5 Ulospora bilgrami Sudan, thorn Non relevant 
6 U/ospora bilgrami Sudan, thorn Nonrelevant 
7 Ulospora bilgrami Sudan, thorn Non relevant 
8 Ulospora bilgrami Sudan, thorn Nonrelevant 
9 Chaetomium brasiliense Sudan, thorn Non relevant 
10 Chaetomium murorum Sudan, soil Non relevant 
dH11971 Phoma Sudan, thorn Non relevant 
dH11983 c Sudan, soil Nonrelevant 
dH11975 Sudan, soil Non relevant 
a CBS 247.48 is considered to be theM mycetomatis reference strain to which the ribosomal 
sequences for the other strains were matched for reasons of 
comparison. 
b "Confident alignment" indicates that difference was Jess than 10%. 
c -, isolates belong to currently undefined fungal species. 
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Table 2: Universal and Madurella-specific primers used for PCR and sequencing• 
Primer Position (gene/nucleotides) Reference Primer sequence (5'---> 3')b 
ITS4 LSU/41-60 23 ~TCCTCCGCTTATTGATATGC 
ITS5 SSU/1745-1767 23 GGAAGTAAAAGTCGTAACAAGG---> 
V9D SSU/1609-1627 6 TTAAGTCCCTGCCCTTTGTA---> 
LS266 LSU/287-266 19 ~GCATTCCCAAACAACTCGACTC 
NS1 SSU/20-38 23 GTAGTCATATGCTTGTCT---> 
NS24 SSU/1769-1750 10 ~AAACCTTGTTACGACTTTTA 
Oli5 SSU/83-102 14 GAAACTGCGAATGGCTCATT---> 
Oli9 SSU/573-591 14 CGCGGTAATTCCAGCTCCA---> 
Oli10 SSU/951-935 14 ~TGGYRAATGCTTTCGC 
Oli11 SSU/962-980 14 TTRATCAAGAACGAAAGT---> 
Oli13 SSU/1418-1438 14 ~ATAACAGGTCTGTGATGCCC 
Oli14 SSU/1418-1438 14 ATAACAGGTCTGTGATGCCC---> 
26.1N ITS2/111-130 2 ~AATGAGTTGGGCTTTAACGG 
28.3N ITS1/474-494 2 TCCCGGTAGTGTAGTGTCCCT---> 
a Positions correspond to the Saccharomyces cerevisiae consensus sequence. 
b R = purine A or G; Y = pyrimidine Cor T. 
c Primer sequences and positions are based on theM. mycetomatis ITS sequence (GenBank 
accession no. AF162133). 
RESULTS 
Cultivation and identification of soil- and thorn-borne fungi. Overall, 43 soil samples and 35 batches of 
thorns were analyzed for the presence of black-pigmented fungi resembling M. mycetomatis. Ultimately, 52 
colonies from 24 samples were subcultured in a pure form on SDA. Strains were studied microscopically 
and by molecular analysis. None of the strains turned out to represent M. mycetomatis based on either 
morphological criteria or ribosomal sequencing. Some of the strains were excluded prior to sequencing 
based on ribosomal gene RFLP analyses (result not shown). Sequence results are listed in Table 1, 
presenting data for 13 environmental, 6 clinical, and 5 reference isolates. M. mycetomatis CBS 247.48was 
found to be practically identical (0- to 3-bp difference) to six strains of cases of mycetoma from Sudan. CBS 
247.48 might be Gammel's strain from Cleveland, Ohio, dating from 1927, which is the type strain of 
Madurelfa americana. Three further clinical strains putatively representing M. mycetomatis (CBS 201.38 
from Indonesia, CBS 248.48 from New Mexico, and CBS 217.55 from Argentina) were found at some 
distance but could be aligned with confidence. M. mycetomatis CBS 216.29 from Italy was found to be 
different from both clusters. About 105 out of 190 positions of ITS1 and about 140 out of 160 positions of 
ITS2 of M. mycetomatis could be aligned with environmental Chaetomium species from Sudan. which were 
identified down to the species level by morphology and by comparison with sequences from the public 
domain. Three strains from Sudanese soil were found to be members of Pleosporales with distoseptate 
conidia, viz. Exserohilummcginnisii, Bipolaris papendorfii, and Bipolaris spicifera. Their ITS sequences 
showed no homology with Leptosphaeria. Five strains from Sudanese thorns and showing superficial 
resemblance to one of the known agents of mycetoma, Neotestudina rosatii, were morphologically 
identified as Ulospora bilgramii (13). Five reference strains of N. rosatiiwere clearly different but could be 
aligned with confidence. The type strain of N. rosatii CBS 427.62 originated from a case of mycetoma, 
whereas the remaining four strains were environmental (not shown in Table 1). 
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Although it is unlikely that M. mycetomatis in nature is present in the same form it is in patients, it is 
suggested that the isolation of this species directly from the environment is very difficult using the current 
protocols. Despite failed attempts to culture the organism, we now present data showing that it is possible 
to detect M. mycetomatis in the environment of areas in Sudan where it is endemic by molecular methods. 
In addition, thorny A. maflifera bushes, which are very common in the region sampled and are responsible 
for a high number of thorn pricks, were shown to occasionally harbor the same species of fungus. This 
supports the observation of Abbott (1) that the frequency of mycetoma is associated, albeit weakly, with the 
presence of thorny trees. The low recovery rate suggests, however, that M. mycetomatis is not an ordinary 
sa probe on the thorns. 
Human subcutaneous inoculation apparently is an efficient selective means for recovery of the fungus. A 
comparable situation is known in black yeast-like fungi, where Cladophialophora bantiana (11) and 
Fonsecaea pedrosoi (De Hoog et al., unpublished data) are homologous examples. These fungi are thus 
far known only from mammals and can be obtained from the environment after mouse passage only. 
Interestingly, F. pedrosoi is one of the agents of chromoblastomycosis, which is also a mycosis associated 
with (minor) trauma. 
Other fungal species (anamorph genera Bipolaris, Drechslera, and Exserohilum) were frequently isolated 
from soil in Sudan. Among these was E. mcginnisii, which thus far is only known from a single strain from a 
human patient and hence has been regarded as a true pathogen. However, its occurrence in the 
environment suggests that this is also one of the saprobes which only occasionally is able to infect a 
human host. 
In conclusion, we have demonstrated the presence of M. mycetomatis DNA on or in Acacia thorns and in 
soil samples. The fungal prevalence in the soil especially suggests that this may be the prime reservoir 
from which infections originate. This is further corroborated by the fact that clinical isolates and 
environmental strains seem to share the same ribosomal genotype, confirming that at least the same fungal 
species is concerned. The challenge for current research is to elucidate the processes that underlie the 
culture-refractory nature of environmental M. mycetomatis isolates. Whether or not the fungus readily 
adapts to humans provides another interesting and important research topic. 
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ABSTRACT 
The genus Madurel/a, described for non-sporulating agents of human mycetoma, is proven to be 
heterogeneous on the basis of rONA SSU and ITS sequencing data. Madurella mycetomatis, the main 
agent of mycetoma in arid zones of Central and East Africa, probably belongs to the ascomycete order 
Sordariales. Madure/la mycetomatis, the generic type species, is neotypified. M. grisea, with world 
wide occurrence, is likely to be a member of the order Pleosporales, just as the mycetoma agents of 
Leptosphaeria, Pseudochaetosphaeronema and Pyrenochaeta. Neotestudina rosatii belongs to the 
order Dothideales. Judging from ITS data, M. mycetomatis and N. rosatii are species complexes. The 
ex-type strain of N. rosatii, from a human mycetome, has an ITS sequence that deviates from that of 
environmental strains of the species. 
INTRODUCTION 
Eumycetoma is a massive subcutaneous fungal infection from which the etiological agent emerges in 
the form of more or Jess compact mycelial grains. The immune response is a granulomatous foreign 
body reaction (26) characterized by local necrosis and the formation of fistels (28, 42). The disorder is 
supposed to originate from accidental traumatic inoculation of plant material such as thorns or 
splinters contaminated with fungi. For example, Abbott (1) noted a history of thorn pricks in 10 out of 
62 cases of mycetoma and in two of these found thorns still embedded in infected tissue. Basset eta!. 
reported on two cases with thorns inside lesions from which Leptosphaeria senega/ensis Segretain et 
a!. and Pyrenochaeta romeroi Borelli could be isolated (7). Judging from these case histories it is likely 
that the agents of mycetoma reside in the environment in regions endemic for the disease. They are 
supposed to be saprotrophic fungi able to survive hostile conditions in their natural niche and able to 
cause mycoses in humans when inoculated by coincidence. 
However, recent findings on Madurel/a mycetomatis (Laveran) Brumpt are not in line with this view. 
This species is preponderant in cases of eumycetoma in Sudan. Abbott reported 1231 cases in a 2.5 
year period (1 ). Ahmed eta!. noted that clinical isolates are genetically identical (2). This suggests that 
Jiving human tissue provides a suitable source for growth of the species. The fungus thus must 
possess a specialized pathogenic potential, which is unlikely for a saprotroph on plant material. 
The genus Madurel/a was defined primarily for sterile mycelia (22). Hence, degenerate cultures may 
easily have been mistaken for that species. De Hoog et a!. found that strains from imported cases of 
mycetoma in The Netherlands and originally identified as M. mycetomatis actually concerned a wide 
diversity of degenerate fungal strains (21). In the present study M. mycetomatis is taxonomically 
redefined by comparing superficially similar clinical and environmental strains with reference strains 
from an established culture collection (2). Fresh isolates originated from Sudan, which is a part of a 
'mycetoma-belt' with further foci in southern India, Somalia and Senegal (41 ). This endemic area is 
characterized by an arid and hot climate with 50-500 mm rainfall concentrated in short periods 
between June and October. 
MATERIALS AND METHODS 
Culture conditions. Environmental isolates from Sudan are those listed by Ahmed eta!. (2). Clinical 
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isolates were obtained by deep biopsy at the Mycetoma Research Center, Khartoum, Sudan. They 
were maintained on malt extract agar (MEA) slants at 24°C and transferred to fresh tubes every six 
months. Reference strains, selected from genera which in the literature were reported to comprise 
agents of eumycetoma (Table 1), were retrieved from the collection of the Centraalbureau voor 
Schimmelcultures (Utrecht, The Netherlands). 
DNA extraction. Two protocols were used: 
1. About 1 cm2 of mycelium was transferred to a 2 : 1 mixture of silicagel and Celite 545 with 300 J.ll 
CTAB-buffer (Tris.HCI, 200 mM, pH 7.5; Na-EDTA, 200 mM; NaCI 8.2%; cetyltrimethylammonium 
bromide [CTAB] 2%). The material was ground with a micropestle (Eppendorf). After adding 200 J.ll 
CTAB-buffer and vigorous shaking the sample was incubated for 10 min in a 65°C waterbath. 500 J.JI 
Chloroform was added, vortexed briefly and centrifuged for 5 min at 14,000 rpm. After transferring the 
aqueous supernatant to a new Eppendorf tube, 2 volumes (-800 J.ll) ethanol 96%, -20EC were added 
and mixed gently. The DNA was precipitated at -20°C for at least 30 min. The pellet obtained by 
centrifuging 5 min at 14,000 rpm was washed twice with 500 J.JI ethanol 70%, -20°C. The DNA was 
dried overnight at room temperature and suspended in 97.5 J.ll TE-buffer (1 0 mM Tris, 10 mM Na-
EDTA, pH 8.0) with 2.5 J.ll RNAse-solution (10 mg pancreatic RNAse 20 Ulmg in 1 ml 0.01 M Na-
acetate). Samples were incubated for 5-30 min at 37EC and stored in a refrigerator. 
2. The FastDNA® Kit (Bio101, Carlsbad, Ca., U.S.A.) was used with 1 cm2 of mycelium homogenized 
with a Lysing Matrix and Cell Lysing Solution (CLS-Y) in the FastPrep® Instrument. After 
centrifugation a Binding Matrix containing guanidine thiocyanate was added to the supernatant. The 
bound DNA was washed with Salt/Ethanol Wash Solution (SEWS-M) and collected with a DNA Elution 
Solution (DES). When checked on 1% agarose gel, the FastDNA® Kit resulted in a better quality of 
DNA, but less quantity. 
PCR. The rONA Internal Transcribed Spacer (ITS) region was amplified with primers V9G and 
LS266(32). Other primer combinations (V9G I ITS4, LS266 I ITS5) were used in case of negative 
result. The near-complete SSU rONA gene was amplified with primers NS1 and NS24-UCB (31) and 
sequenced with primers listed by De Hoog eta/. (22). Of several programs used, optimal results were 
obtained with the following: predwell (94°C, 5'), then 30 cycles of denaturation (94°C, 1 '), annealing 
(48°C, 1 ')and elongation (72°C, 2'), followed by postdwell (72°C, 3'). One unit Super-Taq polymerase 
(ITK Diagnostics, Leiden, The Netherlands) was used for a 50 J.ll reaction mixture with 2 J.ll raw DNA. 
In some cases 6% dimethylsulfoxide (Merck) was added. Amplicons were purified using GFX™ and 
Gel Band Purification Kit (Amersham Pharmacia, Roosendaal, The Netherlands). DNA was bound to 
the GFX-column with a Capture-buffer (containing acetate and chaotrope), washed with a wash-buffer 
(containing Tris-EDTA and ethanol) and collected with TE-buffer. Concentrations of amplicons were 
estimated by comparison with known concentrations of SmartLadder (Eurogentec, Seraing, Belgium) 
on a 1% agarose gel. 
RFLP. Twenty two environmental and 14 reference strains were used for a Restriction Fragment 
Length Polymorphism (RFLP) analysis of the ITS spacer domain amplified with primers ITS1 and ITS4 
(58). Eight J.ll of the amplicon solution was incubated with two units of the endonucleases Hhal and 
Haelll (Amersham Pharmacia) at 36EC overnight. 
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Sequencing and identification. The sequencing reaction was carried out with 15-50 ng of DNA for a 
10 j.JI reaction including 4 pmol primer and 4 j.JI BigDye RR Mix (Applied Biosystems, Nieuwerkerk 
a.d. IJssel, The Netherlands) using primers ITS1 and ITS4 (58) for the ITS region or Oli1, Oli5, Oli9, 
Oli10, Oli11, Oli13 and Oli14(53) for the SSU gene with 25 cycles, as follows: 96°C, 10"; 50°C, 5"; 
60°C, 4'. DNA was precipitated with ethanol and sequenced on an ABI Prism™ 310 Genetic Analyzer 
(Applied Biosystems) automated capillary sequencer. The sequences were adjusted using SeqMan of 
Lasergene software (DNAStar, Madison, Wisconsin, U.S.A.) and aligned using BioNumerics (Applied 
Maths, Kortrijk, Belgium). Sequences were compared to a set of dedicated sequences available for 
research purposes at CBS. This database was made on the basis of the known spectrum of agents of 
mycetoma (Table 1; taxonomic relationships according to De Hoog et a/.(22)). Groups of agents with 
strictly uncoloured hyphae were not taken into account In case no match was found they were run 
against the GenBank sequences using BLASTn (5). 
Tree reconstruction. A distance tree of near-complete SSU rONA sequences was generated using 
Neighbor joining algorithm with Kimura correction in the TREECON package (version 1.3b) (57); 
bootstrap values were calculated from 100 re-sampled data sets. 
RESULTS. 
Selected strains analyzed are listed in Table 2. Since many of them failed to produce reproductive 
structures in vitro, strains potentially matching M. mycetomatis were screened by using RFLP of the 
rONA ITS region. The Sudanese strains from cases of mycetoma had profiles identical to those of five 
M. mycetomatis reference strains from the CBS collection (CBS 247.48, 216.29, 201.38, 217.55) and 
of Madurella sp. CBS 248.48. The set of remaining mycetoma strains compared, comprising 
Pseudochaetosphaeronema, Pyrenochaeta, Leptosphaeria, Neotestudina, as well as Madurella grisea 
MacKinnon et a/. and CBS 868.95 of M. mycetomatis, were consistently different One strain of M. 
mycetomatis, CBS 246.66, appeared to be misidentified, as it was found to be identical to M. grisea 
(Table 2). 
ITS sequence data (not shown) of M. mycetomatis, CBS 247.48 was found to be nearly identical (1-7 
bp difference) to five strains from cases of mycetoma in Sudan and two in Mali. CBS 247.48 is 
possibly Gammel's (29) strain from the U.S.A., which may be the ex-type strain of Madurella ikedae 
Gammel; we were unable to ascertain the history of this strain in the CBS archives. Four further 
clinical strains, CBS 201.38, from Indonesia, CBS 248.48, from New Mexico, U.S.A., CBS 216.29, 
from Italy, and CBS 217.55, from Argentina, clustered at significant distance (average 5.3%) but could 
be aligned with confidence. The differences were not detected by Haelll and Hhal digestion. None of 
these isolates was a type strain of any described species. The distance from M. mycetomatis involved 
38 bp. Variability within the group was noted at 8 positions, none of which was phylogenetically 
informative. Distances to remaining species compared were too large to allow meaningful tree 
reconstruction. Nearest neighbours found in GenBank were members of the genera Thie/avia, 
Corynascus and Chaetomium; all are classified in the ascomycete order Sordariales. Only partial ITS 
alignment was possible with corresponding sequences of M. mycetomatis, as they deviated at least 
9%. M. mycetomatis CBS 868.95, isolated in The Netherlands from a patient originating from the 
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Caribbean, was very different and could not be aligned to any of the fungi mentioned above. 
Sequencing of the total SSU rDNA gene of M. mycetomatis, CBS 247.48 revealed that Chaetomium 
elatum Kunze:Fr. (GenBank M83257) was its nearest neighbour (Ascomycetes: Sordariales), at 6 bp 
difference (Fig. 1). Further genera found close to CBS 247.48 were Neurospora, Sordaria and 
Podospora, which all belong to the order Sordariales. 
Sequencing of the total SSU rDNA gene of an authentic strain of Madurella grisea, CBS 331.55, 
revealed that it clustered in the middle of a clade with species of the genera Leptosphaeria, 
Cucurbidothis, Westerdykel/a, Sporormia and related genera (Fig. 1 ), with Leptosphaeria bico/or D. 
Hawksworth et a/. as its nearest neighbour at 89 bp difference. All these genera are members of 
ascomycetes known to belong to the order Pleosporales. 
ITS sequences of species of M. mycetomatis, Chaetomium, and other members of Sordariales could 
not be aligned to any of the above species with purported affinity to the order Pleosporales including 
M. grisea; even partial alignment did not produce acceptable levels of confidence. A separate 
comparison was therefore made for M. grisea with the coelomycetous agents of eumycetoma 
Pyrenochaeta romeroi, P. mackinnonii Borelli and Pseudochaetosphaeronema larense (Borelli & 
Zamora) Punithalingam, plus the ascoma-forming agents classified in Leptosphaeria. The mutual 
distances were large (Table 2), with percentages difference between 27.5 and 31.2. Only very small 
parts of the ITS regions of the extremes of the cluster, i.e. Leptosphaeria senegalensis and L 
thompkinsii EI-Ani on the one hand and Madurel/a grisea on the other, could be aligned with 
confidence. Two strains of M. grisea, CBS 331.50, CBS 332.50 (both authentic strains from J.E. 
MacKinnon), and one of M. mycetomatis, CBS 246.66, were found to be identical to each other. This 
species took a rather isolated position. ITS regions of other members of the Pleosporales, such as 
Alternaria, Bipolaris and Curvu!aria, could not be aligned to the remaining pleosporalen fungi (data not 
shown). 
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Table 1: Genera containing agents of mycetoma with their proposed phylogentic position, the later 
taken from de Hoog eta/. (22) and from the present paper. Genera containing established agents (22) 
are printed in bold type; occasional agents are cited with reference to case reports. 
Name Order Grain Reference 
Fusarium falciforme* Hypocreales White 
Acremonium kiliense Hypocreales White 
Acremonium cf. potronii Hypocreales White (17) 
Acremonium recifei Hypocreales White (18) 
Cy/indrocarpon cyanescens Hypocreales White (19) 
Cy/indrocarpon destructans Hypocreales White (60) 
Fusarium vertici!lioides Hypocreales White (4) 
Fusarium so/ani Hypocreales White (33) 
Phialemonium obovatum (originally Hypocreales White (36) published as Acremonium hyalinulum)(dog) 
Aspergillus flavus Eurotiales White (59) 
Aspergillus hollandicus (=A. vitis) Eurotiales White (17, 44) 
Aspergillus nidulans Eurotiales White (8, 41) 
Bipolaris spicifera Pleosporales Black (34, 49) 
Corynespora cassiicola Pleosporales Black (40) 
Curvu/aria geniculata (dog, horse) Pleosporales Black (9, 12, 13) 
Curvu/aria lunata Pleosporales Black (12, 38, 41) 
Leptosphaeria senegalensis Pleosporales Black (50) 
Leptosphaeria thompkinsii Pleosporales Black (27) 
Madurella grisea Pleosporales Black (52) 
Pseudochaetosphaeronema larense Pleosporales Black (11) 
Pyrenochaeta mackinnonii Pleosporales Black (10) 
Pyrenochaeta romeroi Pleosporales Black 
Madurella mycetomatis Sordariales Black 
Phaeoacremonium parasiticum Sordariales Black (37) 
Neotestudina rosatii Dothideales White (35) 
Exophiala jeanse/mei Chaetothyriales Black (43) 
Phialophora verrucosa Chaetothyriales Black (45, 56) 
Rhinoc/adiella atrovirens Chaetothyriales Black (25) 
Pseudallescheria boydii Microascales White 
Polycytella hominis Microascales White (15) 
Trichophyton Onygenales White 
Dermatophyte Onygenales White (16) 
* Until recently known as Acremonium falciforme (54) 
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Table 2: Madurel/a strains identit:i 
Original name Number Source Locality ITS differences Final 
% IP b.p identification 
Sordariales: 
M. mycetomatis CBS Foot Sudan 0 8 M. mycetomatis 
109801NT 
M. mycetomatis CBS 247.48 Foot USA 0 8 M. mycetomatis 
M. mycetomatis CBS 110359 Foot Mali 0 8 M. mycetomatis 
M. mycetomatis P2 Foot Mali 0 8 M. mycetomatis 
M. mycetomatis DH11854 Foot Sudan 0 8 M. mycetomatis 
M. mycetomatis DH11849 Foot Sudan 0 8 M. mycetomatis 
M. mycetomatis DH11850 Foot Sudan 0 8 M. mycetomatis 
M. mycetomatis CBS 110087 Foot Sudan 0 8 M. mycetomatis 
M. mycetomatis CBS 216.29 ? Italy 5.3 38 8 M. species 1 
M. mycetomatis CBS 201.38 Foot Indonesia 5.3 38 8 M. species 1 
M. mycetomatis CBS 217.55 Hand Argentina* 5.3 38 8 M. species 1 
M. species CBS 248.48 ? New 5.3 38 8 M. species 1 
Mexico 
Dothideales: 
N. rosatii CBS 331.78 Seed India 39.5 23 i 1 
N. species 1 
N. rosatii CBS 628.74 Soil Egypt 39.5 23 1 N. species 1 
N. rosatii CBS 271.75 Soil India 39.5 23 1 N. species 1 
N. rosatii CBS 690.82 Seed Japan 39.5 23 1 N. species 1 
N. rosatii CBS 247.62T Foot Somalia 38.5 0 0 N. rosatii 
U. bilgramii DH11974 Thorn Sudan 38.6 37 0 U. bilgramii 
U. bilgramii CBS 110020 Thorn Sudan 38.6 
l 
37 
l 
0 U. bilgramii 
U. bilgramii DH11978 Thorn Sudan 38.6 37 0 U. bilgramii 
U. bilgramii DH11979 Thorn Sudan 38.6 37 0 U. bilgramii 
U. bilgramii DH11980 Thorn Sudan 38.6 37 0 U. bilgramii 
Pleosporales: 
M. grisea CBS Foot Argentina 0 0 M. grisea 
331.50AUT 
M. grisea CBS Foot Chile 0 0 M. grisea 
332.50AUT 
M. mycetomatis CBS 246.66 Jaw India 0 0 M. grisea 
Pseud. larense CBS 640.73T Man Venezuela 27.5 Pseud. larense 
Pyr. mackinnonii CBS 674.75T Man Venezuela 30.3 Pyr. mackinnonii 
Pyr. mackinnonii CBS 110022 Foot Mexico 30.4 Pyr. mackinnonii 
Pyr. romeroi CBS 252.60T Man Venezuela 29.0 Pyr. romeroi 
L. thompkinsii CBS 200.79 Man Senegal 29.6 L. thompkinsii 
L. thompkinsii CBS 201.79 Man Senegal 29.6 L. thompkinsii 
L. senegalensis CBS 196.79T Man Senegal 31.2 L. senegalensis 
Phylogenetic position doubtful: 
M. mr_cetomatis CBS 868.95 Foot Aruba** M. species 2 
Note: ITS differences: IP = Informative positions (mutations and indels) compared to flanking species 
(direction of comparison indicated by arrows); b.p = single nucleotide polymorphisms (mutation and 
indels) listed as variance within the species; if not alignable with confidence, a percentage difference 
over ITS domain is listed only. L=Leptosphaeria; M=Madurella; N=Neotestudina; Pseud = Pseudo-
chaetosphaeronema; Pyr =Pyrenochaeta; U =U/ospora; 
*Reference number (47); **Reference number (24). 
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Five strains from Sudanese thorns, isolated during a search for environmental strains of M 
mycetomatis (2), were morphologically identified as U/ospora bi/gramii (D. Hawksworth et a/.) D. 
Hawksworth et a/., a species with close morphological similarity to the known agent of mycetoma, 
Neotestudina rosatii Segretain & Destombes (Dothideales) (35). The ITS sequences differed in 37 bp 
from the ex-type strain of N. rosatii (Table 2), CBS 427.62, but could be aligned with confidence. CBS 
427.62 originated from a case of human mycetoma in Somalia, a country located in the dry climate 
zone of eastern Africa. Four environmental strains in the CBS collection, morphologically identified as 
N. rosatii, proved to differ from CBS 427.62 in 23 positions (Table 2). The deviating strains all 
originated from (sub)tropical countries outside Africa. ITS sequences of neither U/ospora nor 
Neotestudina were alignable to M mycetomatis or M. grisea. 
DISCUSSION 
Two diametrically opposing theories on the etiology of human eumycetoma have appeared in the 
literature. The classical view (hypothesis-1) is that a relatively limited list of causative agents exists, 
which contains established pathogens typically causing mycetoma. A widely used list is that of Rippon 
(48). The view is supported by the overrepresentation of a small number of species involved in the 
numerous reported cases of eumycetoma, such as Acremonium spp., Pseudal/escheria boydii (Shear) 
McGinnis eta/. and Madurefla spp. 
Alternatively (hypothesis-2) it has been suggested that mycetoma is an unspecific reponse to the 
subcutaneous inoculation of a wider range of principally saprotrophic agents. There are three 
arguments supporting this view. The first of these is theoretical: it is difficult to imagine how a fungus 
can be successful in its evolution when it is dependent on the unnatural situation of being traumatically 
introduced into its host. Accidental infections ecologically must be a 'spill-over', because no 
transmission to another host is possible (22, 46). Secondly, when more ecological data become 
available on agents of mycetoma such as P. boydii or A. kiliense GrOtz, it is realized that even the 
most common species on Rippon's list of agents of mycetoma actually have another ecological 
behaviour as mainstay, in which subcutaneous growth in humans is insignificant (6, 23, 30). Thirdly 
and perhaps most importantly, there are large problems with the correct identification of agents of 
mycetoma. Most agents show poor morphological differentiation or are sterile, and hence, given 
Rippon's restricted list of well-known etiologic agents, a clinician can easily pick one of these names 
for the isolate at hand (48). This was underpinned by De Hoog eta/., who showed that only a small 
portion of the agents from imported cases in The Netherlands actually concerned recognized 
members from Rippon's list (21, 48). It was therefore surmised that anything cultivated from a 
subcutaneous grain and showing reduced growth without reproduction in vitro might incorrectly be 
identified as 'Madurel/a'. 
Recent molecular data suggest that both suppositions are partly correct (2, 3). The spectrum of 
potential agents is larger than anticipated and includes a number of undescribed taxa, favouring 
hypothesis-2. On the other hand, in geographically limited areas a marked preponderance is noted of 
one or a few fungal species only, suggesting correctness of hypothesis-1. Strains identified as 
Madurelfa indeed represent a delimited taxonomic entity, rather than an amalgam of poorly 
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differentiated strains. Below the currently known species of Madurella and their relatives, and 
Neotestudina-like fungi isolated from the M. mycetomatis endemic zone, are discussed. 
Madurella mycetomatis 
Thirumalachar & Padhye obtained M. mycetomatis from soil, although at an extremely low recovery 
rate (55). Ahmed eta!. found that M. mycetomatis was detectable from culture-negative environmental 
samples by nested PCR (2). When the species is extremely refractory to direct isolation, 
subcutaneous inoculation of M. mycetomatis into living mammal tissue apparently enhances growth of 
the fungus. A comparable situation is known in black yeast-like fungi, where C!adophialophora 
bantiana (Sacc.) Gerrits van den Ende and de Hoog eta/. (32) and Fonsecaea pedrosoi (Brumpt) 
Negroni (20) were shown to contain only clinical strains, environmental isolation being possible only by 
enrichment in living mammal tissue. Interestingly, F. pedrosoi is one of the agents of 
chromoblastomycosis, which is also a post-traumatic (sub)cutaneous mycosis. The supposition that 
traumatically inoculated species are likely to be strict saprotrophs is falsified for at least some fungi. 
M. mycetomatis is likely to be restricted to Sudan and adjacent countries for climatic reasons. Ahmed 
eta!., using ITS RFLP, found all clinical strains from Sudan to be identical to CBS 247.48. This was 
confirmed by sequence data of the same domain (2, 3). Proven cases caused by this species 
originated from Sudan and Mali (Table 2), both countries having a desert-like climate. CBS 247.48 is 
probably Uudging from correspondence of J.A. Gammel in the CBS archives) the ex-type strain of 
Madurella ikedae Gammel, currently a synonym of M. mycetomatis (22). In that case the strain would 
originate from a case of eumycetoma in Texas, U.S.A., a region also having a dry climate (29). The 
CBS collection holds a number of strains from other climatic zones which showed more than 5% ITS 
difference and thus are likely to be a separate species (Table 2). A precise taxonomic definition of M. 
mycetomatis (s. str.) is overdue. 
No holotype material of M. mycetomatis is known to be preserved. Laveran (39) described the first 
fungal isolate from a case of mycetoma from Djibouti, at about 1000 km east of Khartoum (Sudan), as 
Streptothrix mycetomi Laveran. Streptothrix is a genus of Actinomycetes. Therefore Brumpt erected 
the genus Madurella for fungal agents of mycetoma producing grains in tissue, in vitro exuding a 
brownish pigment into the medium and remaining sterile (14). He renamed Laveran's species as 
'Madurella mycetomt (correct Latin isM. mycetomatis). Clinical strains tend to produce sclerotium-like 
bodies in vitro on casein-agar. Brumpt's description exactly matches the prevalent genotype isolated 
from clinical cases around Khartoum, and therefore we have no doubt that this is indeed the taxon that 
was described by Laveran (3, 14, 39). We indicate one of the Sudanese strains, CBS 109801, from a 
mycetoma of the foot of a human patient, as neotype of M. mycetomatis. Using SSU and ITS rONA 
sequence data, the ascomycete genus Chaetomium (Sordariales) was found among the closest 
relatives of M. mycetomatis. This suggests that M. mycetomatis is a sterile member of the order 
Sordariales (14). 
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Figure 1: Distance tree of the Ascomycota based on 157 near-complete SSU rONA 
sequences, constructed with the Neighbor joining algorithm with Kimura correction in the 
Treecon package. Bootstrap values >90 from 100 resampled datasets are shown. 
Pneumocystis carinii was selected as out-group. 
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Four CBS strains, originally identified as M. mycetomatis, showed significant ITS deviations from M. 
mycetomatis, and are hence likely to represent a separate species. None of these strains was of 
African origin. Strain CBS 868.95 (from Netherlands Antilles, as M. mycetomatis) could not be aligned 
with confidence and must represent a very different fungus. It had white-greyish rather than yellow-
brown colonies, grew faster on SGA and did not produce any extracellular pigment. The SSU rONA 
gene had an intron between the ITS1- and ITS5-primer regions. A sterile isolate of Pseudallescheria 
boydii was surmised, but no match could be found in Genbank. These data prove that "Madurefla" is 
currently applied as an umbrella term covering partly unrelated species. The large number of obsolete 
names in the literature necessitate a taxonomic study into the genus Madurel/a (22). 
Madurella grisea 
M. grisea has been encountered in South America and India, but not in the dry climate zones of Africa 
(Table 2). ITS sequences of two authentic strains were found adjacent to Leptosphaeria thompkinsii 
and could largely be aligned with this species. M. grisea may thus be a member of Pleosporales and 
hence unrelated to M. mycetomatis. This supposition was confirmed by SSU rONA sequencing data, 
where the species was found close to Leptosphaeria bico!or and Cucurbidothis pityophila Petrak, 
though at 54 bp distance from the latter. Among the species currently most similar to M. grisea based 
on ITS data are Pseudochaetosphaeronema larense, known from a single case of human mycetoma 
(11) and several Leptosphaeria species from mycetomata (Table 2). Reported clinical cases in 
Senegal, occasionally showing thorns embedded in granulomata, concerned Leptosphaeria 
senegalensis and Pyrenochaeta romeroi, rather than M. mycetomatis (7). The climate in Senegal is 
more humid than in Central and East Africa, where plant remains are strongly desiccated. 
Neotestudina rosatii 
The ex-type strain of N. rosatii, CBS 427.62, a member of the order Oothideales, originated from a 
case of human mycetoma (51). The remaining strains morphologically identified as N. rosatii deviated 
significantly in ITS sequence profiles by 14 substitutions in ITS 1 and 9 in ITS2, and 7 lndels in ITS1 
and 2 in ITS2, and thus are likely to represent a cryptic species. These strains came from soil and 
from seeds of Coriandrum and Cuminum. N. rosatii is an extremely rare species on which very few 
reports are available, neither clinical nor environmental. In contrast, Ulospora bi/gramii, a close relative 
of N. rosatii, was isolated repeatedly from thorns of a Balanitis egyptica tree in Sudan (Table 2)(35). 
This species differs from N. rosatii including the cryptic species by having furrows on the surface of the 
ascospores while N. rosatii ascospores are smooth-walled (35). The ITS rONA Ulospora I 
Neotestudina cluster could not be aligned with any of the remaining species analyzed in this study. In 
GenBank no sequences with a close match were found. 
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ABSTRACT 
Molecular diversity among clinical Madurelfa mycetomatis isolates, the prime fungal agent of human 
mycetoma in Sudan, could possibly explain the diverse clinical presentations of this severely 
debilitating infectious disease. In addition, culture-independent DNA mediated typing tests need to be 
developed for this organism since M. mycetomatis DNA but not the organism itself can be identified in 
soil, the material from which infections are thought to originate. A collection of 38 different clinical M. 
mycetomatis isolates was characterised by large scale random amplification of polymorphic DNA 
(RAPD) using 20 different primer species. These analyses, involving at least 2600 annealing sites, 
showed a complete lack of DNA fingerprint variation between the various isolates. From the resulting 
homogeneous DNA fingerprints seven fragments were cloned, sequenced and novel, species-specific 
PCR restriction fragment length polymorphism (RFLP) tests were designed. The seven PCR RFLP 
tests were successfully performed on the 38 different M. mycetomatis strains. However, again all M. 
mycetomatis DNA patterns obtained appeared to be identical, whereas patterns produced using DNA 
from related species were clearly discriminatory. These results suggest that there is little genetic 
variation among clinically relevant M. mycetomatis strains from Sudan. These data cautiously imply 
that different manifestations of mycetoma are due to differences in host susceptibility rather than 
differential virulence of the causative agent. 
INTRODUCTION 
Mycetoma presents as a chronic, relatively painless, subcutaneous, granulomatous lesion which is 
characterised by the formation of multiple sinuses. In approximately 40% of all infections a fungus is 
the causative agent, the sclerotia of which are shed through these sinuses in the form of fungal grains 
(11, 8). The colour of these grains has diagnostic value. Green grains identify Aspergillus flavus as the 
most likely causative agent, whereas white grains are usually produced by Pseudoalfescheria boydii, 
Aspergillus nidulans or Acremonium kiliense. Brownish grains are produced by Neotestudina rosatii, 
whereas deep-black grains are produced by species such as Curvularia lunata, Phialophora jenselmi, 
Pyrenochaeta romeroi, Leptosphaeria senegaliensis, Madurelfa grisea or Madurella mycetomatis. This 
latter fungus is the most prevalent mycetoma agent in Sudan (8). Although this agent has been shown 
to occur in various geographic regions, most cases of M. mycetomatis mycetoma occur in a relatively 
comprehensive "mycetoma belt" (e.g. (1 )). Although the precise mechanism of infection remains 
enigmatic, it is frequently suggested that traumatic inoculation of fungus-containing soil, assisted by 
the presence of plant materials such as thorns, provides a likely route of dissemination (8, 9, 11, 15). 
However, growing the organism from soil has been documented only sparsely, although recent 
molecular detection has revealed that fungal DNA can be detected quite easily in soil from different 
regions in the mycetoma belt (1 ). Because of the apparent impossibility of culturing the fungus directly 
from soil it is very hard to study the precise transmission routes of the fungus. Since M. mycetomatis 
DNA can be easily amplified from soil, development of methods for further analysis of the genetic 
variation in this soil-embedded material has a high priority. Tools for the assessment of strain-specific 
characteristics may also be helpful for distinguishing relapsing disease from re-infection events. For 
the reasons outlined above we have tried to develop direct DNA identification assays suited for the 
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discrimination between Sudanese M. mycetomatis strains. Using a large collection of clinical isolates 
of M. mycetomatis we tried to identify polymorphic genome fragments suited for direct DNA 
characterisation. Strains were initially typed by high-throughput random amplification of polymorphic 
DNA (RAPD). Possible sequence variability within individual RAPD fragments was investigated by the 
application of PCR restriction fragment length polymorphism (RFLP) tests. 
MATERIALS AND METHODS 
Strains and culture conditions. The Sudanese M. mycetomatis strains (n = 38) were identified by 
PCR as previously described by Ahmed et a!. (2). Strains were isolated by direct culture of black 
grains obtained from deep biopsies of patient lesions at the Mycetoma Research Center, Khartoum, 
Sudan. Patients originated from a large geographic region, essentially covering the entire Sudanese 
mycetoma belt. Strains were maintained on Sabouraud agar (Difco Laboratories, Becton Dickinson, 
USA) with gentamicin at an incubation temperature of 37°C. Examples of M. mycetomatis-related 
organisms were obtained from the CBS (Centraalbureau voor Schimmelcultures, Utrecht, The 
Netherlands). These fungi were: Alternaria infectoria (CBS 160.79), Alternaria tenuissima (CBS 
160.52), Alternaria alternata (CBS 137.90), Curvularia geniculata (CBS 731.96), Curvulaira 
verrucu/osa (CBS 444. 70), Pseudallescheria boydii (2 different strains) (CBS 883.71 en CBS 
1003.92), Leptosphaeria tompkinsii (CBS 201.79), Bipolaris hawaiiensis (CBS 727.96), Exophiala 
jaenselmei (CBS 635.69), Phialophora verrucosa (CBS 839.69), Aspergillus fumigatus (dH 12472), 
Penicillium crustaceum (CBS 581.67), Fusarium oxysporum (CBS 1098.98), Fusarium so/ani (CBS 
1022.56), Cylindrocapron /ichenico/ (CBS 623.92) and M. grisea (CBS 172.22). 
DNA isolation. After 4 weeks of incubation at 37°C the fungal material was excised from the agar and 
transferred into 6 ml of a 0,9% NaCI solution. The material was sonified for 2 minutes at 30 micron 
(Soniprep 150, Beun de Ronde, Abcoude, The Netherlands) to fully disrupt the mycelium. Five 
hundred microlitres of this suspension was taken and DNA was isolated according to the DNA 
extraction method described by Boom eta/. (6). Because of the low amount of DNA isolated with this 
method an alternative method was used too. After sanification, the suspension was frozen in liquid 
nitrogen, thawed and ground in a mortar using a porcelain pestle. DNA was extracted from this 
emulsified sample using the Wizard® Genomic DNA Purification Kit (Promega Corporation, Leiden, 
The Netherlands) employing the Yeast protocol which starts by the addition of the Nuclei Lysis 
Solution. 
Randomly amplified polymorphic DNA analysis. The RAPD reactions were performed in 50 ~I 
reaction volumes containing 5 ~I 1 Ox Supertaq PCR buffer 1 (HT Biotechnology Ltd., United Kingdom), 
10 ~I 1 mM PCR nucleotidemix (Amersham Life Sciences, Roosendaal, The Netherlands), 0,5 ~I 
primer at 50 pmol per ~I; 1.2 U Supertaq (HT Biotechnology Ltd.) and distilled water to complete the 
volume. The twenty primers used are listed in Table 1. The PCR reaction was performed in a model 
60 Thermocycler (Biomed, Theres, Germany). PCR was composed of a pre-denaturation step of 4 
minutes at a temperature of 94°C and 40 cycles of each a denaturation step of 1 minute at 94°C, an 
annealing step of 1 minute at 25°C and an extension step of 2 minutes at 74°C. The RAPD patterns 
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PCR-products with a similar size as those of M. mycetomatis were analysed by RFLP involving two 
enzyme-combinations. Only in case of the 814/813 PCR product of M. grisea some restriction 
fragments had an identical size as the restriction fragments obtained from M. mycetomatis. 
Essentially, all species could be differentiated from the M. mycetomatis strains. The data for the other 
primers showed similar species specificity, albeit that DNA from other species than described above 
resulted in amplification of multiple DNA fragments or non-amplification at all (data not shown). 
Table 1: Primers used for the high throughput RAPD analysis of 38 clinical Madurella mycetomatis 
isolates 
Primer Primer Primer sequence Nucleotide size of the 
number name amelimers synthesised 
13 ERIC-2 AAGTAAGTGACTGGGGTGAGCG 550,900,1100 
26 REP-21 ICGICTTATCCIGGCCTAC 950, 1300, 1500 
46 RAPD1 GGTTGGGTGAGAATTGCACG 200,300,500,550,700 
47 random GGCCATAGAGTGTTGCAGACAAACTGC nothing amplified 
51 random GCGATCCCA 500,550,720 
52 RAPD7 GTGGATGCGA 500,550,600,800,820, 
1500, 1550 
174 VanC2 CTTCCGCCATCATAGCT nothing amplified 
214 CEP PA480 GTTACCAACAGAATAAGC nothing amplified 
312 PC2 GCCTTCTCCAATGCAGCGAC 450,900 
449 28.3b TCCGCGGGGCGTCCGCCGGA 650,710,950,1100 
548 wlaclus1 ATCAGATCGTTCCTATACAG nothing amplified 
683 uspA2repeat1 TGGATATGATAGAGATTTTTCCAT 600,620,630,750,800, 
900, 1100, 1400, 1500, 
1550 
689 campcoli1 AGGCAAGGGAGCCTTTAATC 600,620,800 
695 Ca1E1 TATGACAAACACAGGGACAAC 600, 1100, 1150,1400, 
1500, 1550 
699 McCAACrep GTCGGTATTATGGGCAG 700,900,950,1000, 
1100,1300,1500 
701 repeatF1 AGGATTTGGCGAAGTTTGG 700, 800, 950, 960, 1000, 
1100, 1250, 1260, 1350, 
1550, 1560, 1600, 1650 
714 PstBseq1 TAGTCTGGTGGCTGGTGTGGGC nothing amplified 
718 PstSprer AACTTTCATAATGTCTCCTG 500 
729 13,1VNTR TGAACCATGGGTAAATTTGA nothing amplified 
786 AW-14.2 GCTTATCGTAAAGTAAACGA nothing amplified 
Table 2: RAPD fragments cloned and used for the PCR RFLP procedure. 
Frag. RAPD Frag. Seq Seq Forward primer Reverse primer Ann. 
nr primer size length hamal Number sequence Number sequence Temp. 
1 695 600 585 none 989 AGAAAGCGGACGGAGAGCAAJ:..ATG 990 TATGACAAACACAGGGACAACGAG 54 
5 701 1550 1467 None 1144 AGGGTGAAIDGAGCCAGTTGAGT 1145 AGTGGGGCGAGTACAGGGATMTA 55 
7 701 1000 811 None 995 TGCTGCTGCTGCTCCTCCTGTTAC 996 CGACTACCACCACCGCCACTACT 59 
8 701 800 682 None 998 AGTTTGGCACGAGGAAGGTCATTG 999 IDGGCGAAGTTTGGGTAGGATGG 54 
15 52 1050 1061 cumA 813 IDCAGGCTCAGGGTGCGTTCGTG 814 GIDAGGTGATGCCGGTGTATGGT 56 
16 52 800 793 None 810 CGGTCGGCGGTTAGAGAAAT 411 TCGGGGGCCACTGCTGCTA 50 
17 46 450 439 None 1192 TGCACGTGGAATCGCATMTMTA 1193 TCGGGGGCCACTGCTGCTA 55 
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DISCUSSION 
Classical high-throughput RAPD and newly developed PCR-RFLP tests were applied to detect 
possible genetic variation among different clinical M. mycetomatis strains from Sudan. The RAPD 
results were frustrating: out of twenty primer species employed 25% did not result in any DNA 
amplification, whereas the remaining 75% generated completely identical patterns for all of the strains 
analysed. Several thousands of annealing sites were scanned and the complete Jack of variability is at 
least remarkable. For most micro-organisms, including eukaryotes, RAPD is a technique well suited 
for the detection of genetic diversity in and between different species. RAPD studies performed with 
other clinically relevant fungi, such as A. fumigatus, resulted in many different genotypes, even when 
only limited numbers of primers and fungal strains were employed. Bertout eta/. defined 8 different 
genotypes among 52 A. fumigatus isolates (4), while Bart-Delabesse et a/. detected 31 different 
genotypes in 67 isolates (3). These are only two examples of the many which can be found. Examples 
for fungal species as diverse as Ma/assezia spp., Histoplasma capsulatum, Exophiala dermatitidis and 
Blastomyces dermatitidis have been published in the past and all of these studies successfully 
demonstrated genetic diversity among strains (16, 17, 19, 20). On the other hand, past studies on 
Naegleria spp revealed that for this species RAPD analysis was similarly homogeneous in its outcome 
(18), although a far smaller number of primers were used. The conclusion based on the RAPD 
analysis can only be that the M. mycetomatis isolates collected from infections in the Sudanese 
mycetoma belt are strongly clonal. 
The observations outlined above were further corroborated by PCR-RFLP, which again did not reveal 
any genetic variation between the isolates (1, 2). Firstly, all the PCR primers selected from the 
sequences of the RAPD fragments that were cloned reacted positively with the DNA from all 38 
strains. Apparently these randomly selected priming sites were well conserved. Secondly, all PCR 
products derived from the various M. mycetomatis isolates presented the same restriction pattern after 
digestion by 6 different enzymes, which is in line with at least species homogeneity. That PCR-RFLP 
can be useful to detect fungal genetic variability has been shown repeatedly before as well (5, 12, 14, 
20). To test if the different primer combinations were species-specific, these were tested on different 
fungal species. It appeared that when amplicons were obtained, the other fungi could be identified on 
the basis of a deviating RFLP pattern. Only for M. grisea and M. mycetomatis similar restriction 
fragments were found. These data demonstrate that significant inter-species variability exists and that 
this variation can be easily documented by PCR RFLP. 
The lack of molecular diversity among M. mycetomatis strains that we document here seemingly 
contrasts with data by Lopes eta/. (13). These authors were able to identify 9 different genotypes in 
17 M. mycetomatis isolates by RAPD and restriction endonuclease assays (REA). These strains were 
obtained from geographically diverse locations. However, two isolates from Sudan could not be 
separated, which is in agreement with our findings. The Sudanese strains clustered with strains from 
Cameroon, Marocco and Chad. We here included two strains from Mali (p1 and p2). Mali is in West-
Africa, while Sudan is in East-Africa; climate and vegetation are completely different in these two 
countries. Still, the strains from Mali had the same genotype in the RAPD as the clinical isolates from 
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RAPD analysis PCR RFLP primers 995/996 
52 51 701 BstUI BsmA+Ddel Hae/1/+Hinf Xho+Haelll 
M 1 2 3 1 2 3 1 2 3 123123123123M 
Figure 1: RAPD and PCR-RFLP analysis of DNA sequence variability in specific regions of the M. 
mycetomatis genome amplified by RAPD primers. 
Sudan. A problem with the Lopes study (13) was that it was not clearly indicated how the strains were 
identified to the species level. 
In our experience, not all Madurella strains are easily identified and misclassification may be an 
explanation for the enhanced levels of genetic heterogeneity encountered by these authors. For 
instance, M. grisea is another member of the same genus, also presents with dark, slowly growing 
colonies of a sterile mycelium and cannot be discriminated easily from M. mycetomatis (15). All 
strains, including the 2 from Mali, that are presented here have been species defined by PCR 
diagnostics (2). 
In conclusion, no sequence heterogeneity was encountered among a large number of clinical isolates 
of M. mycetomatis from Sudanese patients. This indicates that the organism is clonal and makes one 
wonder whether physical boundaries to the mycetoma belt have resulted in the spatial confinement of 
a certain M. mycetomatis clone. This clone is apparently well adapted to its human host, but it is also 
able to persist concealed in the environment. 
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ABSTRACT 
Eumycetoma due to Madurella mycetomatis is a major mycological health problem in endemic areas. 
We infected BALB/c mice (male or female) with various amounts of M. mycetomatis mycelium, 
containing sterilized soil as a natural adjuvant or Freund's incomplete adjuvant. Mice differed with 
respect to age and immune status. Intraperitoneal, subcutaneous and intravenous inoculation was 
explored and survival was monitored. Mice were killed at various intervals after inoculation, checked 
for the presence of the characteristic black grains, and organs were cultured for M. mycetomatis. 
Infected organs were subjected to histopathological examination. Immunocompetent male mice were 
as susceptible as immunocompromised female mice, but showed higher mortality rates. In conclusion, 
a reproducible mouse model of intraperitoneal M. mycetomatis infection with characteristic black 
grains in immunocompetent adult or young female mice was developed. Although this experimental 
model does not simulate macroscopic features of the subcutaneous M. mycetomatis infection in 
humans, the histopathological characteristics of the lesions and the development of black grains are 
clearly representative for the human infection. This model will enable further studies on the 
pathogenesis as well as prevention and treatment of the fungal infection. 
INTRODUCTION 
Mycetoma is a chronic, slowly progressive, relatively painless subcutaneous granulomatous disease, 
which can be caused by fungi (eumycetoma) or aerobic actinomycetes (actinomycetoma). It is 
characterized by swollen lesions and sinuses, through which grains of different color, size and 
consistency are discharged.The organisms that cause mycetoma are presumably soil saprophytes [1 
and 2]. The infection is supposed to originate from accidental traumatic inoculation of plant material 
such as thorns or any other minor trauma that leads to the penetration of the causative organisms into 
the subcutaneous tissues [3, 4 and 5]. The geographical distribution of mycetoma cases and 
mycetoma-causing organisms depends on many factors including temperature, rainfall, type of soil 
and vegetation as well as the demographic variables of the susceptible population. Most mycetoma 
cases are seen in tropical and sub-tropical regions. Males are more frequently affected than females, 
with a sex ratio of 5:1. The disease is frequently seen in young people (20-40 years old), affecting feet 
(70% of cases) or hands (12% of the cases). Infection of other sites such as leg, knee, thigh, 
perineum, back, arms, thorax, shoulders, head, and neck are reported less frequently [4 and 5]. 
Secondary bacterial infections of the mycetoma lesions are often observed, thereby complicating and 
aggravating disease development [6]. 
The fungus Madurel/a mycetomatis is the most prevalent etiological agent of eumycetoma [5]. In 
tissue biopsies it is observed that the fungus produces numerous black grains, composed of 
aggregates of fungal hyphae embedded in a hard extracellular cement material. Early diagnosis 
followed by proper surgical and chemotherapeutic intervention, before bone involvement occurs, 
results in the most successful outcome [5]. However, reports describing successful and lasting 
treatment of advanced eumycetoma due to M. mycetomatis are few and conflicting [4 and 5]. 
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Some investigators were successful in inducing M. mycetomatis infection producing characteristic 
black grains in laboratory animals [9], but reproducibility was poor. Successful infection required 
inoculation of M. mycetomatis, mixed with killed tubercle bacilli or the use of congenitally athymic nude 
mice or immunocompetent mice after repeated intraperitoneal inoculation [7, 8 and 9]. Although some 
of the models appeared to be clinically useful, efforts to reproduce the experimental infection were 
again not successful (e.g. [1 OJ). The determinants important for the establishment of mycetoma in 
experimental animals are thus not yet elucidated. In the present study we describe a reproducible 
infection model for M. mycetomatis in mice. A number of variables were examined, including age, 
gender and immune status of the host, the inoculum of M. mycetomatis, the use of an adjuvant, and 
the route of inoculation. 
MATERIALS AND METHODS 
Animals. Specified pathogen-free male or female BALB/c mice at the age of 5-6 weeks (young) or 
12-13 weeks (adult) were obtained from lffa Credo (L'Arbresle, France). Mice were housed in filtered-
top cages, and supplied with commercial food pellets and sterile drinking water. To prevent bacterial 
super-infection, mice received ciprofloxacin (660 mg r1) and colistin sulfate (100 mg r1) in their 
drinking water during the experiment. The animal experiments ethical committee of the Erasmus 
Medical Center approved the studies described in the current paper. Leukocyte depletion was induced 
by cyclophosphamide (1 00 mg kg-1 intraperitoneally, Sigma-Aldrich Chemie, Steinheim, Germany) 4 
days before fungal inoculation, followed by repeated doses of 75 mg kg·1 starting on the day before 
inoculation with a 3-day interval. This treatment results in persistent granulocytopenia of <Q.1x1Q9 
cells per liter of blood. Corticosteroid treatment was applied by administration of methylprednisolon 
acetate (80 mg kg-1 subcutaneously; Pharmacia and Upjohn, Woerden, The Netherlands) 5 h before 
inoculation followed by repeated doses of 10 mg kg-1 subcutaneously at a 3-day interval. 
Granulocytopenia was not checked for each individual mouse, but was assessed in parallel 
experiments. The number of mice per group varied from 4 to 12. 
Fungal strain. A strain of M. mycetomatis, originally isolated from a mycetoma patient seen in the 
Mycetoma Research Center, University of Khartoum, Sudan, was used in this study. This strain was 
isolated by direct culture of the black grains obtained by deep surgical biopsy and identified by 
morphology and polymerase chain reaction as M. mycetomatis [11]. This isolate was maintained in the 
laboratory for 2 years in Sabouraud agar (Difco Laboratories, Becton Dickinson, Sparks, MD, USA) by 
repeated subculturing every 4-6 weeks. 
Fungal inocula. Fresh inocula were prepared for each experiment. M. mycetomatis was cultured in 1-
2 liters of Sabouraud broth (Difco Laboratories, Becton Dickinson) and incubated at 37"C for 2 weeks. 
Mycelia were separated and washed by vacuum filtration (Nalgene, Abcoude, The Netherlands). Wet 
weights of the mycelia were determined. A suspension containing 300 mg wet weight of M. 
mycetomatis per ml in phosphate-buffered saline (PBS) was sonicated for 2 min at 28 (MSE Soniprep 
150, Integrated Service TCB, USA). This procedure does not kill the fungus, although the remaining 
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hypha I segments appear to be significantly shortened. The main advantage of sonication was the fact 
that inocula were prepared in a more standardized fashion and were prepared more reproducibly. 
Various inocula were prepared by dilution with sterile PBS. The fungal viability in terms of colony-
forming units (CFU) was determined for each inoculum by sub-culturing a diluted sample on 
Sabouraud agar and direct colony counting after 2 weeks incubation at 37"C. The inocula of heat-
killed M. mycetomatis were prepared by autoclaving the viable fungal suspension at 121 oc for 15 min. 
The sterility of these materials was checked for each batch separately by culture assays. As a natural 
adjuvant sterile fine soil in a final concentration of 10 mg mr1 was used. Soil was obtained from 
mycetoma endemic areas in AI Jazirah state along the Blue Nile, Sudan. Also Freund's incomplete 
adjuvant (FIA) (Difco Laboratories, Detroit, Ml, USA) was used in a final concentration of 50% (v/v). 
Animal inoculation. Animals were inoculated with various amounts of viable or heat-killed M. 
mycetomatis, ranging from 0.8 to 140 mg wet weight per mouse. Inoculation was performed either 
subcutaneously in the neck (0.4 ml) or intraperitoneally (0.4 ml). In pilot experiments intravenous 
inoculation (0.2 ml) and subcutaneous inoculation in the foot pad (0.02 ml) or in the abdomen at two 
sites (0.2 ml per site) were performed. 
Assessment. Mycetoma infection was diagnosed when black grains could be observed 
macroscopically after the inoculation of the M. mycetomatis mycelia suspension. To monitor the 
course of the infection, mice were checked daily for survival. Dead mice were dissected and internal 
organs were examined macroscopically for the presence of black grains. Organs were stamped onto 
blood agar and Sabouraud agar (Difco Laboratories, Becton Dickinson), to exclude bacterial super-
infection and to test for the presence of M. mycetomatis by aerobic cultivation. In case of the presence 
of the black grains, culture in Sabouraud agar was performed to test their viability. Also, mice were 
killed at various intervals after inoculation (days 17-51), depending on the immune status of the 
animal and the inoculum used. Blood samples (0.4-0.5 ml) were taken via retro-orbital bleeding under 
C02 anesthesia. The serum was collected and stored at -20°C. During dissection a careful search for 
the presence of black grains was performed. From each mouse, liver, spleen, kidneys, heart and lungs 
were aseptically excised and bacterial and fungal cultures were performed. Representative biopsies 
from different organs, subcutaneous lesions and abdominal lesions were fixed in 1 0% buffered 
formalin and processed. Sections were stained with hematoxylin and eosin, periodic acid Schiff and 
Grocott methenamine silver stain for fungi [24]. Fisher's exact test was used to determine the possible 
significance of differences in the infection and mortality rates between the different groups of mice. 
RESULTS 
For the low inocula of 0.8, 8 and 40 mg wet weight of viable M. mycetomatis a good correlation was 
found in vitro with viable counts being 3x1Q3 , 3x104 and 1.5x105 CFU, respectively. At higher 
inoculum sizes, counting of CFU was less reliable. This is the main reason for using wet weight of the 
fungal material to standardize the inoculum size. Intraperitoneal inoculation with the high inoculum of 
140 mg heat-killed M. mycetomatis in young immunocompetent female mice caused quick death in 
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two out of five mice (data not shown). In all groups, inoculated with viable M. mycetomatis, after 
dissection, the internal organs showed negative cultures forM. mycetomatis. In mice that died during 
the first few days after intraperitoneal inoculation, M. mycetomatis was incidentally isolated from either 
spleen and/or liver. These positive cultures indicate that M. mycetomatis could survive for at least a 
few days in immunocompetent mice. In only one leukocyte-depleted mouse, M. mycetomatis was 
isolated from all internal organs after spontaneous death at day 33 after intraperitoneal inoculation. 
However, this mouse did not show black grains. An apparent difference in the susceptibility to 
infection was found between immunocompetent male and female mice, not in terms of infection rate, 
but in terms of mortality, which was elevated in male mice. Overall 2/8 young females and 4/8 adult 
females in the immune competent group of mice inoculated intra peritoneally with 120 mg of the fungus 
succumbed to the infection. For the young and adult males the figures were 5/8 and 7/8, respectively. 
The cumulative mortality was 6/16 for the females and 12/16 for the males with a two-sided Fisher 
exact P value equaling 0.07. This suggests a certain association, which, however, needs corroboration 
by additional experiments involving larger numbers of experimental animals (work in progress). 
When mycetoma lesions were observed in mice, pathology was similar to that defined for mycetoma in 
man. Black grains surrounded by several zones of inflammatory cells were observed (see Figure 1 C). 
Silver stain of the fungus showed thick wall hyphae embedded in the cement material protecting the 
fungus from the immune system [5, 20 and 21]. The fungal black grains were usually attached to 
internal organs, surrounded by fibrous tissue. Sinuses did not develop in case of superficial 
mycetomas after intraperitoneal inoculation, but sinus-like structures were observed occasionally after 
subcutaneous inoculation in all groups (see Figure 1A). The grains were black, irregularly shaped and 
hard in consistency (see Figure 1 B). 
Only a few abdominal or subcutaneous sterile abscesses (incidence Jess than 1%) were seen in all 
mouse groups injected with the heat-killed inocula, but infection did not develop within 51 days with 
interim assessment at days 17 and 38. Material derived from the abscesses always scored negative in 
the culture-based detection assays. 
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Figure 1: A: Adult corticosteroid-treated female BALB/c mouse at day 17 after subcutaneous 
inoculation of 40 mg of M. mycetomatis mycelia and 4 mg sterile soil. Before dissection, a big 
subcutaneous nodule with a healed sinus was seen (left). After killing the mouse numerous small 
black grains characteristic for M. mycetomatis lesions were seen (right). B: Adult immunocompetent 
male (left) and female (right) BALB/c mouse intraperitoneally inoculated with 120 mg fungal mycelia 
and soil adjuvant. The mice showed massive mycetoma lesions in the abdomen. Black grains, which 
are surrounded by fibrous capsules and attached to the peritoneal wall, liver, spleen and other internal 
organs are clearly visible. Mice were dissected 38 days after inoculation. C: Stained histology sections 
of the mycetoma lesion of a mouse intraperitoneally inoculated with 40 mg fungal mycelia and soil 
adjuvant. The left section, hematoxylin and eosin (100x), shows one black grain (arrow) surrounded 
by inflammatory cells similar to that described in human mycetoma. In the inner zone, neutrophils are 
the predominant cells, followed by a middle zone containing histocytes. The right section, Grocott 
methenamine silver stain (400x), shows intact growing fungal hyphae embedded in hard cement 
material protecting the fungus from surrounding inflammatory cells. Mice were dissected at 17 days 
after inoculation. 
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M. MYCETOMA TIS INFECTION 
Adult immunocompetent female BALB!c mice infected intravenously, subcutaneously or 
intraperitoneal/y. Intravenous inoculation or subcutaneous inoculation in the foot pad or abdomen at 
two sites did not result in the development of M. mycetomatis infection (data not shown). As shown in 
Table 1 most of the mice tolerated subcutaneous inoculation in the neck and showed a good survival 
rate. Only two mice died during the first week after inoculation of 80 mg. Infection did not develop after 
subcutaneous inoculation in the neck even with the highest inoculum of 120 mg. All mice developed 
subcutaneous abscesses or nodules, never containing black grains, which reached their maximum 
size in the first 2 weeks, then started to resolve and disappeared completely within 4-5 weeks. Only 
mice infected intraperitoneally showed typical mycetoma lesions with characteristic black grains. 
These mice showed mortality when relatively high inocula were injected. Infection rates after 
intraperitoneal inoculation increased with increasing inocula. The infection was characterized by 
typical mycetoma lesions and numerous black grains. 
Young immunocompetent and adult corticosteroid-treated or leukocyte-depleted female 
BALB!c mice infected intraperitoneal/y. In comparison to adult immunocompetent mice (Table 1), 
adult corticosteroid-treated mice (Table 2) showed similar survival rates, whereas higher infection 
susceptibility was noticed in young immunocompetent and adult leukocyte-depleted mice. The 
difference, however, was not statistically significant (P=0.07 and P=0.12, respectively) (Table 2). 
Abdominal mycetomas with many black grains were seen in young immunocompetent mice starting 
from the inoculum of 8 mg in which two out of eight mice developed infection. The infection rates were 
inoculum-dependent, and at high inocula were comparable to the infection rates seen in the adult 
immunocompetent mice. 
Young and adult immunocompetent male BALB/c mice infected intraperitoneally. There were no 
differences in infection rate between the young and the adult immunocompetent male BALB/c mice 
(Table 3). Compared to young and adult immunocompetent female mice (Table 1 and Table 2) male 
mice showed similar infection rates. However, infected male mice died more quickly before the 
dissection days with numerous black grains. 
Young immunocompetent female BALB/c mice infected intraperitoneal/y, role of adjuvant. The 
data in Table 4 show that the addition of an adjuvant to M. mycetomatis is important for the 
development of the infection. After inoculation of 100 mg M. mycetomatis without adjuvant, only one 
mouse had a single black grain attached to the spleen. Addition of soil or FIA to the same inoculum 
significantly increased the infection rates (8/12 and 7/11, respectively). The difference in the infection 
rates when using the soil adjuvant or FIA was statistically significant (P=0.009 and P=0.009, 
respectively), but no significant difference was observed between the use of soil or FlA. Soil was used 
as the standard adjuvant (Table 1, Table 2 and Table 3), except in those experiments designed to 
study adjuvant activity (Table 4). 
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Table 1: Course of M. mycetomatis infection in adult immunocompetent female BALB/c mice infected 
via subcutaneous or intraperitoneal routes of inoculation. 
Inocula• per mouse 0.8 mg 8mg 40mg 80 mg 120 mg 
Subcutaneous 
Survival rateb 4/4 4/4 4/4 6/8° 8/8 
Infection rate in surviving mice 
at day 17 0/4 0/4 0/4 0/4 0/4 
at day 38 N.D N.D N.D 0/2 0/4 
at day 51 N.D N.D N.D N.D N.D 
Total infection rate in mice 0/4 0/4 0/4 0/6 0/8 
Intraperitoneal 
Survival rateb 8/8 8/8 7/8° 1/7c 4/8° 
Infection rate in surviving mice 
at day 17 0/4 0/4 1/3 1/1 212 
atday38 N.D N.D N.D 2/2 
at day 51 0/4 0/4 2/4 N.D N.D 
Total infection rate in mice 0/8 0/8 3/7 1/1 4/4 
• Inocula of M. mycetomatis contained 4 mg sterile soil (regardless of the inoculum size). All mice were 
infected with inocula ranging from 0.8 to 120 mg. 
b Number of surviving mice/total number of mice. 
c Mice died during the first week, due to toxic side effects, and were excluded from the calculation of 
the total infection rates. 
NO: not done. 
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Table 2: Course of M. mycetomatis infection in young immunocompetent and adult corticosteroid-
treated or leukocyte-depleted female BALB/c mice infected via the intraperitoneal route of inoculation. 
Inocula• per mouse 0.8mg 8 mg 40mg 80 mg 100 mg 120 mg 140 mg 
Young immunocompetent 
Survival rateb 10/10 8/8 6/8c 6/8c 6/8c 6/8c 1/1 oc 
Infection rate in surviving mice 
at day 17 0/4 2/4 1/4 1/3 N.D 3/3 N.D 
at day 38 N.D N.D N.D 2/3 3/6 3/3 1/1 
at day 51 0/6 0/4 1/2 N.D N.D N.D N.D 
Total infection rate in mice 0/10 2/8 2/6 3/6 3/6 6/6 1/1 
Adult corticosteroid-treated 
Survival rateb 8/8 8/8 5/8c 
Infection rate in surviving mice 
at day 17 0/4 0/4 2/3 
at day 38 N.D N.D N.D 
at day 51 0/4 0/4 1/2 
Total infection rate in mice 0/8 0/8 3/5 
Adult leukocyte-depleted 
Survival rateb 8/8 5/8c 2/8c,d 
Infection rate in surviving mice 
at day 17 1/4 1/3 1/2 
at day 38 N.D N.D N.D 
at day 51 0/4 2/2 
Total infection rate in mice 1/8 3/5 2/3 
a Inocula of M. mycetomatis contained 4 mg sterile soil (regardless of the inoculum size). Young mice were 
infected with inocula ranging from 0.8 to 140 mg. lmmunocompromised mice (corticosteroid-treated or leukocyte-
depleted) were infected with inocula ranging from 0.8 to 40 mg. 
b Number of surviving mice/total number of mice. 
c Mice died during the first week, due to toxic side effects, and were excluded from the calculation of the total 
infection rates. 
d One mouse died with many black grains at day 32 after inoculation, this mouse was considered infected. 
NO: not done. 
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Table 3: Course of M. mycetomatis infection in young and adult immunocompetent male BALB/c mice 
infected via the intraperitoneal route of inoculation 
Inocula• per mouse 40mg 80mg 120 mg 
Adult 
Survival rateb 8/8 8/8 1/8c,d 
Infection rate in surviving mice 
at day 17 1/4 4/4 1/1 
at day 38 2/4 4/4 
Total infection rate in mice 3/8 8/8 6/6 
Young 
Survival rateb 7/8° 8/8 3/8° 
Infection rate in surviving mice 
at day 17 0/3 3/4 1/1 
at day 38 0/4 2/4 2/2 
Total infection rate in mice 1/8 5/8 8/8 
a Inocula of M. mycetomatis contained 4 mg sterile soil (regardless of the inoculum size). All mice 
were infected with inocula ranging from 40 to 120 mg. 
b Number of surviving mice/total number of mice. 
c Mice died with many black grains between days 2 and 5, these mice were considered infected. 
d Two mice died during the first week, due to toxic side effects, and were excluded from the calculation 
of the total infection rates. 
Table 4: Course of M. mycetomatis infection in young immunocompetent female BALB/c mice infected 
via the intraperitoneal route of inoculation with 100 mg of M. mycetomatis without or with adjuvant: 4 
mg sterile soil or 50% (v/v) FlA. 
Survival rate• 
Total infection rate in micec 
Without adjuvant 
12/12 
1/12 
Soil adjuvant 
12/12 
8/12 
FIA 
11!12b 
7/11 
a Number of surviving mice/total number of mice. 
b One mouse died during the first week, due to toxic side effects, and was excluded from the 
calculation of the total infection rates. 
c Infection rate in surviving animals at day 51. 
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Macroscopic and microscopic development of black grains. In 25% of the adult corticosteroid-
treated female mice subcutaneously inoculated with 40 mg mycelium, a big subcutaneous nodule 
containing numerous small black grains was observed (Figure 1A). In intraperitoneally infected 
immunocompetent mice, black grains were seen as early as 5 days after the inoculation in mice that 
died before the scheduled dissection. The grains were black, irregular and hard in consistency (Figure 
1 B). There was no clear correlation between the size of the grains and time of dissection, although 
incidentally higher numbers of larger grains were observed with increasing incubation period. Due to 
the irregularity of the massive abdominal lesions it was considered impossible to count the actual 
number of grains. Intraperitoneal inoculation of the mice with the inoculum of 100 mg induced the 
development of a few to a moderate number of grains, while a slight increase of the inoculum up to 
120 mg resulted in severely infected mice with many black grains. The black grains were surrounded 
by a fibrous capsule attached to the peritoneal wall or internal organs, in particular spleen and liver. In 
some mice it was observed that grains were attached to the diaphragm, but grains were never seen in 
other body compartments. Black grains were never expelled through genuine sinuses. Histological 
examination (Figure 1C) of infected tissues showed typical vesicular type of grains surrounded by 
three zones of inflammatory cells. The first ring of cells around the grains was composed mainly of 
neutrophils, followed by histiocytes and an outer vascular zone. 
DISCUSSION 
Mycetoma is a fungal disease affecting the earning sector in the mostly rural communities of endemic 
areas. Without adequate medical treatment and aggressive surgical intervention, mycetoma remains a 
major mycological health problem in these areas affecting young productive people and leading to 
increased morbidity and detrimental social and economic consequences. Models of mycetoma in 
experimental animals remain extremely important for the study of various aspects of the disease. Very 
little is known on the pathogenesis and pathology of mycetoma, and one very attractive area of 
research is the study of therapeutic responses to the broad range of antimicrobial agents presently 
used in clinical practice. In case of bacterial mycetoma (actinomycetoma), considerable success has 
been achieved, in which the major infectious agents have been successfully used for infection in 
laboratory animals [12, 13, 14, 15, 16 and 17]. However, in case of fungal mycetoma (eumycetoma), 
only few investigators have been successful in developing an animal model [8, 9, 10 and 18]. 
The aim of our study was to develop a reproducible infection model for the fungus M. mycetomatis [5]. 
In humans, the fungus produces numerous black grains, which are composed of aggregates of the 
fungal hyphae embedded in a hard extracellular cement material. In the present paper, an infection 
model for M. mycetomatis in young or adult immunocompetent female BALB/c mice is described. 
Many variables were included in the study. Different routes of inoculation were compared, including 
subcutaneous inoculation in the neck, in the abdomen or in the foot pad. Also intraperitoneal and 
intravenous routes of inoculation were applied. In addition, the infection rate was investigated in mice 
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in relation to age, gender, immune status and addition of adjuvant. Abdominal mycetoma with 
numerous black grains developed a few weeks after intraperitoneal inoculation of the fungal mycelia 
suspension in the presence of sterile soil or FlA. After subcutaneous inoculation black grains 
developed only in immunosuppressed mice, while abdominal mycetoma was seen after intraperitoneal 
inoculation in all mouse groups regardless of their immune status, age or gender. 
Establishment of subcutaneous infection in immunocompetent mice was not successful, which is in 
agreement with the studies of other investigators [7, 8 and 10]. Subcutaneously inoculated mice 
developed subcutaneous nodules within 2 weeks. From that time onwards discharge of the inoculum 
itself to the skin surface of the nodules through draining sinuses was observed. This may explain why 
subcutaneous mycetoma with black grains did not develop. 
Young immunocompetent mice and adult leukocyte-depleted mice showed increased susceptibility to 
infection compared to adult immunocompetent mice. As most patients with M. mycetomatis infection in 
endemic areas appear to be immunocompetent, we prefer to elaborate on the infection model in 
young or adult immunocompetent mice. Recent reports, however, stated that one of the predisposing 
factors for acquiring mycetoma might be a partial suppression of cell-mediated immunity [4], 
substantiating previous suggestions by some investigators [8, 12 and 19]. In the present study we 
demonstrate that the M. mycetomatis infection can be produced in immunocompetent as well as 
immunosuppressed mice, thereby suggesting that immune depletion is indeed not needed for the 
development of mycetoma. Our data do not permit speculation on persistence versus clearance of the 
fungus. Although our data suggest that the fungus is present persistently, especially when mice are 
inoculated intraperitoneally, it is unclear whether or not the mice are capable of suppressing the 
infection as time proceeds. Additional studies should be performed, especially in case the model is 
going to be used for testing the efficacy of antifungal agents. 
Most of the previous work in experimental animals such as rabbits, mice, rats, and guinea pigs failed 
to result in reproducible models with high infection rates. Already in 1957 Borelli was able to develop 
M. mycetomatis infection in immunocompetent rats using cultures of M. mycetomatis mixed with either 
Blastomyces dermatitidis or Histoplasma capsu/atum [18]. Murray eta/. [9] were also able to develop 
mycetoma in immunocompetent mice with characteristic black grains when the inocula were mixed 
with killed Mycobacterium tuberculosis. None of these investigations have been easily reproduced by 
other researchers [9 and 10]. Mahgoub and his co-workers were able to induce mycetoma due toM. 
mycetomatis only in congenitally athymic nude mice, three out of eight inoculated mice were infected 
[8]. In recent work, Cremer eta!. [7] did not use immunosuppression or adjuvant in their mouse model 
of M. mycetomatis infection. Black grains were seen microscopically only after repeated intraperitoneal 
inoculation, while black grains did not develop after subcutaneous inoculation. From the present study 
and the work of others, it seems that using adjuvant is necessary to induce mycetoma due to M. 
mycetomatis. Another factor and perhaps more important is the use of relatively high inocula 
containing at least 40 mg wet weight of the fungal mycelia. This study shows that the infection rate is 
inoculum-dependent and that the mice were able to clear relatively low inocula. 
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Factors determining the susceptibility of man and animals to mycetoma remain unclear. Only few 
people in the endemic areas develop mycetoma, although all share a similar risk through, for instance, 
walking barefoot and frequent occurrence of minor trauma due to thorn pricks. Most of the patients in 
the endemic areas are immunocompetent and have no apparent underlying diseases or increased 
susceptibility to the other endemic infectious diseases. 
M. mycetomatis is known to be a sterile fungus. However, the exact nature of the infectious fungus 
particles in the environment is not exactly known, but it is very unlikely that the fungus exists in the 
environment in the same form as in man or animals [22]. Possibly the fungus exists in soil in a 
specialized infectious form or repeated inoculation of small amounts of fungus leads to sensitization 
and higher susceptibility to the infection in man [1 0 and 23]. Alternatively, mycetoma endemic areas 
are also endemic for many infectious parasitic diseases like malaria and worm infections, which could 
prime the immune system, leading to differing susceptibility to theM. mycetomatis infection. 
In conclusion, a reproducible model of intraperitoneal M. mycetomatis infection has been developed in 
young and adult immunocompetent female BALB/c mice. The infection rate was found to be inoculum-
dependent, and inoculation of 120 mg of fungal mycelia results in the development of many black 
grains in around 75% of mice when sterile soil is used as adjuvant. Although this mouse model does 
not exactly simulate the subcutaneous M. mycetomatis infection in man, the histopathological features 
of the lesions and the development of black grains are representative for the human infection. Further 
studies will be performed to investigate the pathogenesis of the disease and the immune response of 
the host although it has to be emphasized that atypical intraperitoneal localization of the black grains 
may be a confounding factor in this respect. The model, however, should prove its value primarily 
during studies on the prophylactic and therapeutic efficacy of antifungal agents. 
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ABSTRACT 
The antifungal susceptibility of 36 Madurefla mycetomatis clinical isolates against amphotericin B and 
itraconazole was determined using an adapted protocol based on the National Committee of Clinical 
Laboratory Standards (NCCLS) guidelines M38-A. Furthermore, the 2,3-bis {2-methoxy-4-nitro-5-
[(sulfenylamino) carbonyi]-2H-tetrazolium-hydroxide} colorimetric assay (XTT test) was used to quantify 
the antifungal activity in terms of reduction of viable fungal mass. Since M. mycetomatis presents as a 
putatively sterile hypha! suspension, visual reading ofthe MIC is difficult, particularly when azoles are used. 
Quantitative determination of the viable fungal mass using the XTT assay was successfully performed for 
both amphotericin 8 as well as itraconazole. The test appeared to be reproducible and sensitive. 
Investigation of 36 independent clinical M. mycetomatis isolates showed that the antifungal effect of 
itraconazole is superior to that of amphotericin B. For amphotericin 8, minimal inhibitory concentrations 
(MICs) ranged from 0.13 to 4 mg/L, the MIC for 50% of the 36 strains (MIC50)was between 0.5 and 1 mg/L. 
For itraconazole MICs ranged from 0.016 to 1 mg/L, the MIC50 varied between 0.06 and 0.13 mg/L. The 
wide range of MICs for both antifungal agents obtained for the clinical M. mycetomatis isolates suggests 
that the introduction of routine antifungal susceptibility testing for this particular species is important for 
adequate therapeutic management, especially for patients not responding to medical treatment. 
INTRODUCTION 
Little is known on the in vitro and in vivo susceptibility towards antifungal agents of the fungus Madurel!a 
mycetomatis, the major cause of eumycetoma. Eumycetoma is a chronic disease, endemic in many 
tropical and subtropical countries (6). Adequate clinical management of the infection requires prolonged 
antifungal treatment combined in many cases with extensive surgical treatment (6, 19). A number of 
antifungal agents is being used for the treatment of eumycetoma, with various degrees of success (1 0). 
Very little data is as yet available regarding the susceptibility of M. mycetomatis to amphotericin B, the 
azoles and the echinocandins. In the past, some reports have promoted ketoconazole as the drug of 
choice in treating eumycetoma patients, sometimes leading to complete cure or, more often, a more limited 
degree of improvement (8, 16, 17). On the whole, the clinical response to ketoconazole is often poor (5, 
19, 20, 26). Other studies show that long term treatment of eumycetoma due to M. mycetomatis with 
itraconazole seems to be the best regimen, although variable responses in patients have also been 
described (5, 10, 19). Particularly in advanced cases of M. mycetomatis eumycetoma the response to 
medical treatment is poor. As the lesions of patients under medical treatment remain localized and well 
encapsulated, it is generally agreed that early diagnosis followed by both surgical and medical treatment 
with appropriate antifungal agents is needed for complete cure (4, 6, 10, 19). Few investigators have 
published in vitro susceptibility data showing that azoles are capable of inhibiting the growth of at least 50% 
of the clinical M. mycetomatis isolates tested. For determination of the in vitro antifungal susceptibility 
pattern of M. mycetomatis strains no proper study using a standardized protocol has been carried out as 
yet. 
In the present study we evaluated the in vitro activities of two antifungal agents, itraconazole and 
amphotericin B, against 36 clinical isolates of M. mycetomatis. Minimum inhibitory concentrations (MICs) 
were determined visually using a modified method based on the National Committee of Clinical Laboratory 
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Standards (NCCLS) guidelines (M38-A) (23). In addition, a quantitative colorimetric method using the dye 
2,3-Bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyi]-2H-tetrazolium-hydroxide} (XTT) was used for 
quantification of the antifungal activity (13, 14, 25). 
MATERIALS AND METHODS 
M. mycetomatis strains. A total of 38 independent clinical isolates obtained from mycetoma patients seen 
in the Mycetoma Research Clinic (University of Khartoum, Sudan) during the year 1999 were included in 
the study. All patients originated from diverse and distant regions in Sudan (data not shown). Two 
additional M. mycetomatis clinical strains, isolated from two mycetoma patients from Mali were obtained 
from Dr. Nicole Desplaces, Croix Saint Simon Hospital, Paris, France (2). All M. mycetomatis strains were 
isolated by direct cultivation of black grains obtained from surgical biopsies. Sabouraud dextrose agar 
(Difco Laboratories, Becton Dickinson and Company, Paris, France) was used for primary fungal isolation 
from clinical specimens. Cultures were maintained by repeated subculture in either Malt extract agar (Difco 
Laboratories, Becton Dickinson and Company, Paris, France) or Sabouraud dextrose agar plates 
supplemented with 80 mg/1 gentamicin (Centrafarm, Etten-Leur, The Netherlands). Species identification 
was determined by morphology and PCR-RFLP as described before (1, 9). 
Antifungal agents. ltraconazole was obtained from Janssen Pharmaceutica Products, Belgium and 
Amphotericin B was obtained from Bristol-Myers Squibb, Woerden, The Netherlands. Stock solutions of 
1600 mg/L were prepared as described by the NCCLS protocol M38-A (23). All stock solutions were 
stored at -80°C. 
In vitro antifungal susceptibility test. The protocol for the susceptibility testing was based on the 
procedure described for filamentous fungi according to the NCCLS guidelines (M38-A) (23) with some 
modifications in inoculum preparation and incubation period. The inocula were prepared from a hypha! 
suspension instead of a conidial suspension. Cultures of M. mycetomatis in tubes containing RPMI-1640 
with L-glutamine (0.3 g/L), 20 mM 3/4-morpholinopropanesulfonic acid (MOPS) and phenol red were 
incubated at 37°C for 5 days. The cultures were sonicated for 20 sec at 28 micron maximum power 
(Soniprep 150, Beun de Ronde, Abcoude, the Netherlands). The sonicated hypha! suspensions were used 
to inoculate 40 mL of RPMI-1640 medium followed by incubation at 37°C for 10 days. Mycelia were 
harvested by 5 min centrifugation at 2158 g and washed once with sterile saline. The pellet was 
resuspended into 15 ml of RPMI-1640 with L-glutamine and MOPS, but without phenol red. To obtain a 
homogenous hypha! suspension, the mycelia were sonicated again. To reduce the effect of surface 
hydrophobicity of the hyphae, Tween-60 (Merck, Amsterdam, The Netherlands) was added in a final 
concentration of 0.05%. The inocula were diluted in RPMI-1640 medium and the transmissions were 
adjusted to 70% at 660 nm using a spectrophotometer (Novaspec II, Pharmacia Biotech). For visual 
determination of the antifungal susceptibility the broth macrodilution method in tubes was applied using 
two-fold dilutions of the antifungal agents according to the NCCLS guidelines. The inoculated tubes were 
incubated for 7 days at 37"C. To avoid confusion due to the nature of the hypha! inocula, additional 
inoculum "reading" controls (hypha! suspension in saline without antifungals) were always included. In 
addition, growth controls (hypha! suspension in RPM! without antifungals) were included. Visually the 
degree of fungal growth was assessed and graded to four scales ranging from score 4 (no reduction in 
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fungal growth) up to score 0 (complete absence of fungal growth). For both amphotericin B and 
itraconazole, MICs were determined as the lowest concentration that prevented any discernible fungal 
growth. 
XTT assay. After visual reading of the antifungal effect the viable fungal mass was determined 
colorimetrically as described by Meletiadis eta/. (21) with some modifications. In short, XTT powder 
(Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) was dissolved in saline to prepare 500 mg/L stock 
solution. A working solution of XTT was prepared by mixing 5 ml of the XTT stock solution with 0.6 ml 1 
mM menadione (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) and 4.4 ml saline. All tubes were 
incubated with 660 111 XTT working solution (250 IJg/ml), and incubated for 2 hat 37"C and for another 3 h 
at room temperature. The tubes were then centrifuged for 1 min at 187 g and 300 111 of the supernatant 
was transferred to flat-bottom microtiter plates. The extinction of the supernatant was measured 
spectrophotometrically at 450 nm in the BioRad model 550 microplate reader (Bio-Rad Laboratories Inc., 
Veenendaai,The Netherlands). 
RESULTS: 
The antifungal activity of amphotericin B and itraconazole against a number of M. mycetomatis isolates 
was determined visually according to the modified NCCLS guidelines and the XTT assay for quantification 
of the viable fungal mass. 
Figure 1 shows the susceptibility of M. mycetomatis strain (mm-55) to amphotericin B and itraconazole, 
respectively, according to the XTT assay. Exposure of mm-55 to increasing concentrations of amphotericin 
B resulted in a concentration-dependent reduction in viable fungal mass, with a sudden switch from no 
reduction to full reduction. Repeating the assay eight times showed highly reproducible results. A 
concentration-dependent gradual decrease in viable fungal mass was observed when rnm-55 was exposed 
to itraconazole. Again the results were highly reproducible. 
In Figure 2, the in vitro antifungal activity of amphotericin B and itraconazole against the M. mycetomatis 
strain mm-55 according to the XTT assay versus the modified NCCLS method are compared. A rapid 
switch from no reduction in fungal growth to absence of fungal growth at increasing concentrations of 
amphotericin B was observed which is in full agreement with the sharp switch in viable fungal mass as 
determined by the XTT assay. The MIC of M. mycetomatis mm-55 for amphotericin B was 2 mg/L. Fungal 
exposure to itraconazole resulted in a concentration dependent gradual reduction in fungal growth 
determined by the modified NCCLS method. Again these results agreed with the gradual decrease in 
viable fungal mass following the XTT assay. The MIC of M. mycetomatis mrn-55 for itraconazole was 0.5 
mg/L. 
Figures 3-5 show the susceptibility of 36 M. mycetomatis clinical isolates determined by the modified 
NCCLS method (Figure 3) or the XTT assay (Figures 4 and 5). Four out of forty Sudanese isolates 
available could not be evaluated as the inocula of 3 isolates could not be homogenized efficiently and one 
isolate did not grow in RPMI medium. The 36 M. mycetomatis strains were tested three times, and the 
median value is presented in the Figures. For amphotericin B, the MIC values (modified NCCLS method) 
ranged from 0.13 to 4 mg/L, the MIC for 50% ofthe 36 strains (MIC50) was between 0.5 and 1 mg/L (Figure 
3). For itraconazole, the MIC values ranged from 0.016 to 1 mg/L, whereas the MIC50 ranged between 0.06 
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and 0.13 mg/L (Figure 3). 
Figure 4 and 5 show the result of the antifungal effect in term of reduction of viable fungal mass. With the 
XTT assay 1 00% reduction in viable fungal mass could not be established for all M. mycetomatis strains as 
a number of strains produced pigments influencing the color intensity. For all 36 M. mycetomatis isolates 
less than 20% of the viable fungal mass remained with amphotericin B in a concentration range of 0.13 to 
16 mg/L. For itraconazole this concentration range turned out to range between 0.016 to 1 mg/L. 
Amphotericin B concentrations and itraconazole concentrations resulting in more than 50% reduction of the 
viable fungal mass ranged from 0.06 to 4 mg/L, and 0.016 to 0.5 mg/L, respectively. 
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Figure 1: Reproducibility of susceptibility testing of M. mycetomatis strain mm-55 against amphotericin B 
and itraconazole using the XTT method. Curves represent the relative extinction at 450 nm for each drug 
concentration compared to the growth control (100%). Assays were repeated eight times. 
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Figure 2: Antifungal susceptibility testing of M. mycetomatis strain mm-55 against amphotericin B and 
itraconazole in duplicate. Curves represent the relative extinction at 450 nm for each drug concentration 
compared to the growth control (1 00%) obtained by the XTT assay. Bars represent the growth levels obtained by 
the modified NCCLS method 
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Figure 3: Antifungal susceptibility of 36 M. mycetomatis clinical isolates against amphotericin B and 
itraconazole according the modified NCCLS method. 
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Figure 4: Antifungal susceptibility of 36 M. mycetomatis clinical isolates for amphotericin B and 
itraconazole resulting in Jess than 20% of viable fungal mass obtained with the XTT assay. 
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Figure 5: Antifungal susceptibility of 36 M. mycetomatis clinical isolates for amphotericin B and 
itraconazole resulting in less than 50% of viable fungal mass obtained with the XTT assay. 
DISCUSSION: 
Conflicting reports of the clinical response of eumycetoma to antifungal treatment. together with evidence 
of varying response of eumycetoma cases to treatment with azoles motivated us to develop a standardized 
method for the antifungal susceptibility testing of M. mycetomatis (19). A standard method for 
determination of the antifungal susceptibility forM. mycetomatis is not available. As a result, limited data 
are available regarding the antifungal susceptibility of this major cause of mycetoma (5, 19, 20, 27). In 
general and unlike bacteria, the different behavior of filamentous fungi makes it impossible to use one 
standard method for antifungal susceptibility testing. Even with the standardized NCCLS documents for 
different groups of fungi, further adaptation is needed for Madurella spp (7, 11 ). The protocol described in 
the present study for susceptibility testing of M. mycetomatis was based on the NCCLS guidelines (M38-A) 
which is the recommended method for spore-forming filamentous fungi such as Aspergillus spp. For these 
fungi, a conidial suspension is used as an inoculum (23). Preparing a standardized inoculum for poorly 
differentiating and hardly- to non-sporulating (sterile) fungal species, like M. mycetomatis, is problematic 
(9). In the present study inocula were prepared from hyphae instead of conidia. To standardize the 
inoculum the harvested hyphae were first homogenized and the inoculum density was set at 70% optical 
transmission as recommended for spores in the NCCLS guideline. The inocula of M. mycetomatis were 
found to be within the recommended range of 0.4 X 104 to 0.5 X 104 CFU per ml (data not shown) (23). 
For amphotericin B, reproducible results with the modified NCCLS method were obtained for 90% of theM. 
mycetomatis isolates included in the study. However, for itraconazole visual reading of the gradually 
decreasing antifungal activity was not always accurate. A wide range of MICs of amphotericin Bas well as 
itraconazole for our clinical isolates originating from the same region was obtained. This is irrespective of 
the fact that based upon genetic parameters all strains seem to be clonally related (3). This implies that 
gene expression differences rather than differential gene presence or absence is a driving factor in the 
development of antifungal resistance. These observations underscore the necessity of antifungal 
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susceptibility testing before or during the treatment of eumycetoma in endemic areas. Assessment of 
antifungal susceptibility may be particularly useful in patients not responding to medical treatment. 
In the present study a second method for antifungal susceptibility testing of M. mycetomatis, the XTT 
assay, was used as well. In this assay the antifungal activity can be quantified by relating the viable fungal 
mass to levels of fungal mitochondrial dehydrogenase activity, converting XTT into formazan, a colored 
end product. The XTT assay was considered to be more appropriate and accurate for determination of 
antifungal susceptibility of M. mycetomatis as the nature of the fungal inoculum is a suspension of hyphae. 
The initial hypha! suspension already shows a significant turbidity which complicates visual reading of the 
inhibition offungal growth. Determination of the antifungal susceptibility of the 36M. mycetomatis isolates 
following the XTT assay generated reproducible data. For amphotericin B the XTT assay showed good 
agreement with the MIC determined by the modified NCCLS method. This overall agreement was also 
documented by Meletiadis et a!. who investigated various other fungal species (21 ). However, for 
itraconazole visual reading of the MICs according to the modified NCCLS method was difficult and was not 
always in agreement with the XTT values. 
Exposure of M. mycetomatis to amphotericin B resulted in a rapid concentration-dependent decline in 
viability, as observed with both methods of susceptibility testing. In contrast, after exposure to itraconazole 
a gradual concentration-dependent effect was seen with both methods. Investigation of 36 clinical M. 
mycetomatis isolates shows that the antifungal effect of itraconazole is superior to that of amphotericin B, 
as confirmed by both methods of susceptibility testing. Approximately 45% of the 36 M. mycetomatis 
isolates were susceptible to itraconazole concentrations less than 0.13 mg/L, whereas amphotericin B was 
not effective at those concentrations. Less than 1 mg/L itraconazole already inhibited the growth of all 36 
M. mycetomatis isolates, whereas at that concentration amphotericin B inhibited the growth of only 21 out 
of 36 isolates. A fourfold increase in concentration up to approximately 4 mg/L amphotericin B was needed 
for prevention of growth of all 36 isolates. Significant variation in susceptibility to both amphotericin B and 
itraconazole between the 36 M. mycetomatis isolates was seen (see Figures 3-5). 
The data from the present study demonstrate that low concentrations of itraconazole are effective in 
inhibiting the growth of M. mycetomatis. This is in agreement with the findings of McGinnis et al. for 
itraconazole and other filamentous ascomycetes (20). Other investigators also found that itraconazole was 
effective in inhibiting the growth of many other clinically relevant fungi. Li and his colleagues showed that 
90% of dimorphic fungi included in their study were inhibited by 1 mg/L of itraconazole (15). Activity of 
itraconazole against dermatophytes (11) and agents of hyalohyphomycosis, phaeohyphomycosis, 
chromoblastomycosis and mycetoma was also demonstrated (20). With respect to clinical efficacy Yera et 
al. recently described that itraconazole has been effectively used for the treatment of a case of fungal 
mycetoma due to Fusarium so/ani (28). 
The in vitro susceptibility of the M.mycetomatis isolates may nominate itraconazole to be the drug of choice 
for the treatment of eumycetoma due to M. mycetomatis. Experience in our clinic also showed that 
itraconazole is effective in treating patients with eumycetoma due to M. mycetomatis. Most of our patients 
showed good a response to long term treatment with itraconazole, although variable responses are also 
seen (unpublished data). Whether these observations correlate with variation in susceptibility to 
itraconazole for theM. mycetomatis isolates is currently not known. Clinical experience underscores that 
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treatment of chronic, advanced eumycetoma requires continuation for a prolonged period of time, even 
when apparent clinical improvement occurs at early stages. In some advanced cases medical treatment 
alone is not enough (22). 
Although amphotericin B is widely used in the treatment of many invasive fungal infections, the future use 
of this drug in mycetoma patients cannot be recommended. About 40% of the M. mycetomatis isolates 
included in this study had an amphotericin B MIG which is higher than the average peak plasma level of 1.5 
mg/L (24). In addition to the relatively low antifungal activity, the requirement for long term treatment of 
mycetoma patients together with the toxicity of amphotericin B further limits its use as a first line 
therapeutic agent. 
In the present study an inoculum prepared from hyphae was used instead of conidia. Manavathu (1999) 
showed that in case of Aspergillus fumigatus similar MIG values can be obtained when using inocula 
prepared from conidia or hyphae. These authors concluded that the physical and biological nature of the 
inoculum hardly affected the measurements (18). In contrast, Guarro and co-workers showed high in vitro 
discrepancies in antifungal susceptibility of filamentous fungi observed when inocula were prepared from 
either hyphae or conidia (12). Here we show that there is essentially no discrepancy between the outcome 
of two methods for assessing the antifungal susceptibility of M. mycetomatis strains. Apparently, the nature 
of the inoculum is not much of a compromising factor. 
In conclusion, a modified protocol based on the NGGLS guidelines (M38-A) was developed and adapted 
for antifungal susceptibility testing of M. mycetomatis. As the inocula are prepared from a hyphal 
suspension, visual reading of the MIG is not always accurate. The XTT assay, allowing colorimetric 
measurement, seems to be preferable for antifungal susceptibility testing of M. mycetomatis since it avoids 
having to read results visually. The XTT assay appeared to be very reproducible and the percentual 
decrease in viable fungal mass can be assessed at different levels, providing additional insight in the 
dynamics of fungal killing. We here show that determination of 50% reduction in viable fungal mass 
probably is appropriate to establish the relative antifungal activity of a number of antifungal agents. The 
present study shows that for the M. mycetomatis isolates tested the antifungal effect of itraconazole is 
superior to that of amphotericin B. Further work is needed to study the in vivo activity of both agents and to 
evaluate the possible correlation between the in vitro results and the clinical response. The recent 
availability of an animal model of M. mycetomatis infection may in the near future assist in the definition of 
the clinical relevance of the susceptibility towards antifungals in establishing adequate therapeutic 
protocols. 
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Mycetoma is a chronic granulomatous subcutaneous infection caused either by bacteria (actinomycetoma) 
or fungi (eumycetoma) (5). Actinomycetoma responds better to antibiotics and other antimicrobial agents, 
whereas eumycetoma is always difficult to treat (11 ). The mycetoma infection is supposed to originate after 
traumatic inoculation of plant materials like thorns or splinters contaminated with the causative agents (5, 
11 ). 
Many studies have been published about mycetoma describing all aspects of the infection. A large number 
of citations can be retrieved from the PubMed-Medline when the search term "mycetoma" is used, but not 
all are actually describing mycetoma. The term mycetoma is often inappropriately used to describe other 
fungal conditions like fungal balls or fungomata (11 ). However, review articles, original papers, case 
reports, letters and other formats describing the history, epidemiology, etiology, pathology, clinical 
presentation and management have appeared in the literature. However, the literature is dominated by 
clinical case reports and case management. Little attention has been paid to basic research on host-
parasite relationships, ecology of mycetoma agents, immunological and molecular characterization of 
mycetoma causative agents, advanced high-tech diagnosis and possible vaccine development. The clinical 
disease and its history, epidemiology, etiology and pathology have been reviewed in chapter 1 of this 
thesis with special emphasis on Madurel/a mycetomatis infection. 
Successful medical and surgical treatment depends on the correct identification of the causative agent (5, 
11 ). Currently available diagnostic tests of mycetoma are few and with many limitations. Direct examination 
of the produced grains is useful in differentiation of mycetoma into actinomycetoma and eumycetoma, but 
especially fungal species identification can not be easily determined. The color of grains may give a clue 
about the possible causative agents (5), but may be also confusing. For instance, both Pseudallescheria 
boydii and Nocardia brasiliensis cause white grains mycetoma. However, the former is a fungus whereas 
the latter is a bacterial species (12). Even if the causative organism is isolated in pure culture, identification 
remains a problem. Many fungi that cause mycetoma remain sterile or show poor morphological 
differentiation (reference 6 and chapter 3). In order to improve the identification of the causative organisms 
of mycetoma we developed a DNA-based technique for the identification of M. mycetomatis, the major 
cause of mycetoma in Sudan and other tropical countries (5, 11 ). We presented for the first time nucleotide 
sequences of the rONA operon of M. mycetomatis. Study of the ITS spacer region in the ribosomal genes, 
showed that clinical isolates of M. mycetomatis from large endemic area belong to the same single 
species. By using this molecular diagnostic technique, M. mycetomatis can be easily differentiated from 
other fungal agents of mycetoma including members of the genus Madurella, such as Madurella grisea. 
Despite the development of conventional mycological techniques for the identification of clinically relevant 
fungi, PCR and sequencing of the ribosomal gene are some times needed for the identification of 
uncommon and poorly differentiated fungi (7). The etiological agents of two unexpected cases of 
eumycetoma were identified by the help of PCR and sequencing as described in chapter 3. Implementation 
of our new test may question the species identification of the causative agents of many previously reported 
cases of eumycetoma. In most reports agents were identified either by culture morphology or 
histopathology alone. The molecular test presented in this thesis may help to identify the real prevalence of 
M. mycetomatis as a causative agent of mycetoma. 
The exact prevalence of mycetoma in endemic areas is not known, but its incidence has been previously 
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described. Abbott in 1956 described the admission of thousands of new cases within a few years in an 
endemic area like Sudan (1 ), with an estimated number of 300-400 new cases each year (9). Climate 
factors, especially the rain fall, were found to be the most important factors affecting the distribution of 
mycetoma causative agents (5). In chapter 4 ecological data of the fungus M. mycetomatis are presented. 
Direct isolation of the fungus from soil and plant materials always failed, although Thirumalachar and 
Padhye were able to isolate M. mycetomatis in a very low recovery rate (13). However, using nested PCR 
M. mycetomatis DNA was detected in 25% of the specimens collected from endemic areas. Our 
observations support the hypothesis that mycetoma agents found in the soil or plants materials in the 
endemic areas are clinically relevant. No teleomorph structures have been described for this fungus. The 
exact nature of the infectious stage in the lifecycle is not known. Natural mycetoma in animals has been 
described, but no other animal or plant reservoir host has thus far been reported.Therefore, further work is 
still needed to provide precise ecological data and to help explaining the pathogenesis of the infection. 
From the current study and the previous work of many investigators, it seemed that the induction of the 
infection in laboratory animal is not easy. Infection of animal needs high inocula in combination with an 
adjuvant. In nature, it is unlikely that the fungus exists in the same form as in cultures and clinical samples. 
In order to resist the harsh environmental conditions during the dry seasons, this fungus should be able to 
develop specialized spores. These spores may have the capacity to induce the infection when accidentally 
inoculated in the subcutaneous tissues. 
In chapter 5 the phylogeny and typification of M. mycetomatiswere addressed. SSU and ITS regions in the 
rONA of M. mycetomatis clinical isolates and other morphologically similar environmental fungal isolates 
were studied. Sequences were compared to reference strains of M. mycetomatisfrom established culture 
collections and with other known agents of eumycetoma. M. mycetomatis and M. grisea are considered to 
be members of a single genus (12). Based on rONA SSU and ITS sequencing data, the two species were 
proven to be heterogeneous. M. mycetomatis is probably belonging to the ascomycete order Sordariales, 
while M. grisea is likely to be a member of the order Pleosporales in the class ascomycete. In addition to 
M. grisea, the order Pleosporales contains other known agents of eumycetoma Leptosphaeria, 
Pseudochaetosphaeronema and Pyrenochaeta. Due to the fact that many microbiologists do not attempt to 
induce sporulation in cultures identified as M. grisea, it is impossible to know how many of these cultures 
are actually Pyrenochaeta mackinnonii (reference11 and figure 1 in chapter 5). These data are also 
supported by the fact that M. mycetomatis and M. grisea have a different geographical distribution (12). 
Neotestudina rosatii, which belongs to the order Dothideales, seems to make species complexes with M. 
mycetomatis. However, sequences data of the SSU and ITS rONA showed that the ascomycete genus 
Chaetomium, in the order Sordariales, is among the closest relatives of M. mycetomatis. This suggests that 
M. mycetomatis is a sterile member of the order Sordariales. 
Two opposing theories about the etiological agents of eumycetoma were also discussed in chapter 5. The 
theory suggesting that wide range of saprotrophic agents can actually cause eumycetoma was strongly 
supported. The problem with the incorrect identification of agents of eumycetoma, leads to the over 
presentation of a limited number of agents. However, it was also found that in some endemic areas a 
limited number of agents are responsible of all eumycetoma cases (2, 3). 
Mycetoma patients have diverse clinical presentations. In order to investigate the possible correlation 
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markers and therapeutic targets. 
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SUMMARY 
Madurella mycetomatis is the most common cause of eumycetoma in tropical and sub tropical 
countries. The mycetoma infection is a serious mycological problem affecting a large number of active 
members of the society in endemic areas. The infection is difficult to treat and has an important social 
and economical impact on affected patients. M. mycetomatis is a fungus showing poor morphological 
differentiation, and identification of the species is always difficult. 
The early diagnosis is one of the key elements mandatory to successful treatment of mycetoma. This, 
however, is not easy due to the many limitations of the currently used diagnostic techniques such as 
direct examination of grains, culture and histopathology. In an attempt to improve the diagnosis, we 
developed a PCR-RFLP procedure for the detection and identification of the fungus in cultures and 
clinical specimens. The M. mycetomatis ribosomal gene complex was amplified and sequenced using 
fungal universal primers. Two sets of species-specific PCR primers were designed. Based on ITS 
sequences and RFLP patterns, clinical isolates from Sudan were found to belong to a single species. 
In chapter 3, complicated eumycetoma cases were reported, in which the etiological agents were 
identified using diagnostic PCR and DNA sequencing. The novel PCR primers were also used for the 
study of the environmental occurrence of M. mycetomatis in endemic regions. Direct cuture-based 
isolation of M. mycetomatis from the patient's surrounding environment failed, but DNA was detected 
in 25% of the environmental specimens (chapter 4). The phylogenetic relationship of M. mycetomatis 
to morphologically similar fungal species was also studied, and its taxonomic position in the fungal 
kingdom was redefined. Our results suggested that M. mycetomatis belongs to the ascomycete order 
Sordariales, while the other proposed member of the same genus "Madurella grisea" likely to be a 
member of the order Pleosporales (chapter 5). 
In order to establish the genetic relatedness of M. mycetomatis clinical isolates, a collection of isolates 
from two endemic foci in Africa were analyzed using large-scale RAPD typing. These analyses 
showed a complete lack of DNA fingerprint variation between the various isolates. These results 
suggest that there is little genetic variation among clinically relevant M. mycetomatis strains from the 
regions involved (chapter 6). 
A reproducible infection model for M. mycetomatis in BALB/c mice was developed. Different routes of 
inoculation, adjuvant types, host immune status, and gender of mice were evaluated. The infection 
was found to be inoculum-dependent with increased infection rates for larger inocula. Adjuvants were 
needed for the induction of the infection (chapter 7). 
The antifungal susceptibility of M. mycetomatis to amphotericin B and itraconazole was studied using 
two new protocols, one adapted from the NCCLS approved guidelines M38-A, the other assay was 
developed to quantify the antifungal activity. Most of the M. mycetomatis clinical isolates were highly 
susceptible to itraconazole, but not to amphotericin B (chapter 8). 
In conclusion, sequence data from the M. mycetomatis rONA were used to develop a novel diagnostic 
PCR-RFLP procedure for the identification of M. mycetomatis in cultures, clinical specimens, the 
environment and for solving diagnostic problems with unexpected, complex patient cases. In addition, 
molecular biological techniques enabled us to study the ecology, taxonomy and phylogeny of M. 
mycetomatis. An infection model in mice was developed and is now ready to be used for the study of 
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the pathology, immunology and the in vivo susceptibility to common antifungal agents of M. 
mycetomatis. 
A sound basis for future research into (early) serodiagnosis, host susceptibility towards M. 
mycetomatis infection and in vivo therapeutic studies has been laid. 
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SAMENVATTING 
De schimmel Madurel/a mycetomatis is de belangrijkste verwekker van eumycetoma in tropische- en 
subtropische gebieden. Mycetoma-infectie is een ernstig mycologisch probleem, waarmee in 
endemische gebieden een belangrijk dee! van de econornisch-actieve bevolking wordt 
geconfronteerd. De infectie is moeilijk te behandelen en heeft een grote sociaal-economische invloed 
op de besmette patient. M. mycetomatis is een schimmel welke morfologisch lastig te identificeren is 
en om die reden is identificatie een moeizame opgave. 
Het sleutelwoord voor een succesvolle behandeling van mycetoma is sneldiagnostiek. Dit is 
momenteel lastig te realiseren, vanwege het gebrek aan adequate diagnostische testen. Een direct 
onderzoek van de schimmelkorrels bijvoorbeeld, is niet erg specifiek. In een paging om deze 
diagnostiek te verbeteren, ontwikkelden wij een PCR-RFLP procedure om potentiele isolaten van de 
schimmel M. mycetomatis uit culturen en klinisch materiaal te identificeren. Een dee! van het 
ribosomale genencomplex van M. mycetomatis werd geamplificeerd m.b.v. universele 
"schimmelprimers" en bovendien werden twee paar soortspecifieke primers op basis van 
sequentieanalyse ontwikkeld (hoofdstuk 2). Op basis van ITS sequenties en RFLP patronen is 
gebleken dat klinische isolaten afkomstig uit Soedan tot een enkele soort behoren. In hoofdstuk 3 zijn 
gecompliceerde cases van eumycetoma beschreven, waarbij de ziekteveroorzakende agentia werden 
aangetoond m.b.v. PCR en DNA sequentie analyse. De nieuwe PCR primers werden ook toegepast in 
een PCR analyse, waarbij de aanwezigheid van M. mycetomatis in omgevingsmonsters van 
endemische gebieden werd onderzocht. Op groei gebaseerde isolatie van M. mycetomatis in de 
directe omgeving van de patient mislukte, maar in 25% van de omgevingsmonsters werd specifiek 
DNA aangetoond (hoofdstuk 4). Eveneens werd de fylogenetische verwantschap van M. mycetomatis 
met morfologisch gelijke schimmelsoorten bestudeerd en de taxonomische positie van dit soort in het 
schimmelrijk werd opnieuw gedefinieerd. Onze resultaten suggereren dat M. mycetomatis 
waarschijnlijk behoort tot de ascomycetenorde van de Sordariales, terwijl een ander lid van dezelfde 
familie, Madurella grisea, waarschijnlijk tot de orde van Pleosporales behoort (hoofdstuk 5). 
Om de genetische verwantschap van klinisch relevante M. mycetomatis isolaten vast te stellen, werd 
een stammencollectie afkomstig van twee Afrikaanse endemische haarden geanalyseerd d.m.v. een 
grootschalige RAPD typeringsonderzoek. Deze analyse toonde het volledig ontbreken van DNA 
"fingerprint" variabiliteit tussen de verschillende stammen aan en suggereerde een compleet gebrek 
aan genetische variatie tussen klinisch-relevante M. mycetomatis stammen in dit gebied (hoofdstuk 6). 
Een reproduceerbaar M. mycetomatis mycetoma infectiemodel in BALB/c muizen werd ontwikkeld. De 
invloed van diverse parameters, zoals de route van inoculatie, het gebruik van adjuvantia, de immuun 
status, de leeftijd en het geslacht van de muizen werden geevalueerd. De infectie bleek afhankelijk 
van de aard van het inoculum te zijn, waarbij de mate van infectie recht evenredig aan de 
inoculumgrootte was. Het toedienen van adjuvantia bleek noodzakelijk voor het succesvol induceren 
van de infectie, de immuunstatus van de gastheer bleek van minder belang (hoofdstuk 7). 
De antifungale gevoeligheid van M. mycetomatis voor amfotericine B en itraconazol werd onderzocht. 
Hierbij werden twee experimentele protocollen voor filamenteuze fungi ontwikkeld en toegepast. Een 
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assay was afgeleid van de door het NCCLS goedgekeurde standaard richtlijn M38-A, met de andere 
assay kan de antifungale activiteit van de middelen kwantitatief gemeten worden. De overgrote 
meerderheid van de klinische M. mycetomatis isolaten vertoonden een hoge gevoeligheid voor 
itraconazol, maar waren in mind ere mate gevoelig voor amfotericine B (hoofdstuk 8). 
Concluderend, de rONA sequentie gegevens van M. mycetomatis werden gebruikt om een 
diagnostische PCR-RFLP techniek te ontwikkelen. De test is bruikbaar om M. mycetomatis uit culturen 
en klinisch materiaal kon worden te identificeren. Bovendien werden moleculair biologische 
technieken toegepast om de ecologie, taxonomie en fylogenie van M. mycetomatis te bestuderen. Een 
infectiemodel in muizen werd ontwikkeld en is nu geschikt om de pathologie, immunologie en de in-
vivo gevoeligheid van M. mycetomatis ten opzichte van de algemeen gebruikte antifungale middelen 
te bestuderen. Voor deze categorie geneesmiddelen werd een in vitro gevoeligheidstest ontwikkeld. 
Een stevige basis voor toekomstig onderzoek in serumdiagnostiek, de gastheergevoeligheid voor M. 
mycetomatis infecties en in vivo therapie studies, is hiermee gelegd. 
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